Etiology and pathophysiology of chronic transplant dysfunction by Kouwenhoven, E.A. (Ewout) et al.
Ewout A. Kouwenhoven 
Jan N. M. IJzermans 
Ron W. E de Bruin 
Received: 2 August 1999 
Revised: 11 April 2000 
Accepted: 27 June 2000 
E. A. Kouwenhoven . J. N. M. IJzermans 
R. W. F. de Bruin 
Department of Surgery, 
Erasmus University Rotterdam, 
P. 0. Box 1738,3000 DR Rotterdam, 
The Netherlands 
R. W. F. de Bruin (m) 
Laboratory for Experimental Surgery 
and Oncology, 
Erasmus University Rotterdam, 
PO Box 1738,3000 DR Rotterdam, 
The Netherlands 
e-mail: debruin@heel.fgg.eur.nl 
Tel.: + 31-10-408-7761 
Fax: + 31-10-408-9471 
Etiology and pathophysiology of chronic 
transplant dysfunction 
Abstract Chronic transplant dys- 
function (CTD) is the predominant 
cause of late graft failure. The com- 
mon histopathological feature in all 
transplanted organs is intimal hy- 
perplasia accompanied by organ 
specific lesions. The knowledge 
about CTD is incomplete, and there 
is no therapy to prevent or treat it. 
This review describes the current 
knowledge on the etiology of CTD, 
with emphasis on kidney trans- 
plants, and postulates a pathophysi- 
ologic route through which CTD 
may develop. 
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The problem of chronic transplant dysfunction 
Since it was first shown in 1954 that successful trans- 
plantation of a healthy kidney could completely rehabil- 
itate an individual with renal failure, transplantation of 
several organs has become an increasingly successful 
medical treatment for patients with end-stage organ 
failure. In 1998, in the Eurotransplant area alone, more 
than 3000 kidneys, 750 hearts, about 1000 livers, 230 
lungs, and about 100 pancreas from cadaveric donors 
were transplanted [9]. Worldwide, 56 intestinal trans- 
plantations were performed in 1996 [70]. The short- 
term results after clinical organ transplantation have im- 
proved progressively. This is principally due to refine- 
ments in tissue typing, advancements in organ preserva- 
tion, operative techniques and ancillary care, more ef- 
fective immunosuppressive agents, and better monitor- 
ing after engraftment. For example, one year survival 
of cadaveric kidneys has increased from approximately 
50 % by the end of the 1960 s, to about 85 % nowadays 
1671, and for living-related kidneys from 80% to 
Despite improving early results, however, it has be- 
come clear that clinical transplantation has not achieved 
its goal as a long-term treatment. For the period beyond 
one year, the annual rate of graft loss has changed less 
since the beginning of the experience. The half-life of 
cadaveric kidney allografts, for instance, has remained 
consistent at 7.5-9.5 years, although the latest United 
States Renal Data System (USRDS) data suggest that 
half-life of first cadaveric kidney grafts is improving 
(Figure 1) [68, 1461. Similarly, the half-life beyond the 
first year of heart transplants is 10.5 years [146]. Other 
organ transplants generally show comparable results, 
with exception of the liver, which shows more favour- 
able long-term results [lo, 981. 
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Years since first transplant 
(CTD) is the most 
important, single cause of late graft deterioration and 
failure. Kidney graft loss is in 35%-58% due to CTD 
[53], more than 70 % of lung allografts had CTD 5 years 
post-transplantation [166]; more than 50 % of the heart 
transplants had severe coronary arteriosclerosis at five 
years [222,231]; and about 9-26 % of graft loss of liver 
transplants was due to CTD [l ,  14,1941. Moreover, a sig- 
nificant number of functioning grafts is lost due to death 
of the recipient. There is still no treatment to inhibit or 
prevent CTD, and a conclusive therapeutic strategy is 
not within hand’s reach since its etiology and patho- 
physiology are poorly known. 
Definition of chronic transplant dysfunction: 
functional and histopathological characteristics 
CTD is a phenomenon in solid organ transplants dis- 
playing a gradual deterioration of graft function months 
to years after transplantation, eventually leading to 
graft failure, and which is accompanied by characteristi- 
cal histological features. Clinically, CTD in kidney 
grafts manifests itself as a slowly progressive decline in 
glomerular filtration rate, usually in conjunction with 
proteinuria and arterial hypertension [150]. In heart 
transplants, CTD presents itself with congestive heart 
failure, acute infarction, arrythmias and, most dramati- 
cally, as sudden death [63]. The diagnosis of liver CTD 
should be based upon clinical evidence of chronic liver 
disease consisting of persistent enzyme abnormalities, 
elevated bilirubin, diminished synthesis of protein and 
blood clotting factors [46, 601. Intractable diarrhoea 
and weight loss are the accompanying symptoms in in- 
testinal transplants with CTD [191]. 
The cardinal histomorphological feature of CTD in 
all parenchymal allografts is fibroproliferative end- 
arteritis [2]. The vascular lesion affects the whole length 
of the arteries in a patchy pattern. There is concentric 
myointimal proliferation resulting in fibrous thickening 
and the characteristic ’onion skin’ appearance of the in- 
tima in small arteries [2]. Other findings include endo- 
thelial swelling, foam cell accumulation, disruption of 
the internal elastic lamina, hyalinosis and medial thick- 
ening, and presence of subendothelial T-lymphocytes 
and macrophages [91]. In addition, a persistent focal 
perivascular inflammation is often seen. Although inti- 
ma1 hyperplasia is very specific for CTD, the diagnosis 
of CTD in biopsies of allografts is frequently based on 
other, less specific abnormalities, since intimal hyper- 
plasia is very patchy and affects mainly arteries larger 
than those seen in biopsies. 
In addition to vascular changes, kidneys undergoing 
CTD also show interstitial fibrosis, tubular atrophy and 
glomerulopathy. Chronic transplant glomerulopathy - 
duplication of the capillary walls and mesangial matrix 
increase - has been identified as a highly specific feature 
of kidneys with CTD [196]. Less specific lesions are 
glomerular ischemic collapse, tubular atrophy, and in- 
terstitial fibrosis. Furthermore, peritubular capillary 
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basement splitting and laminations are associated with 
late decline of graft function [136]. The criteria for his- 
tological diagnosis of CTD in kidney allografts are inter- 
nationally standardised in the BANFF scheme for Re- 
nal Allograft Pathology [195]. 
Until now, such typically functional and histological 
changes of allografts are often diagnosed as ‘chronic re- 
jection’. However, the designation ‘rejection’ presumes 
a host alloimmune responsiveness to be basis for these 
changes. Since there are indications that non-alloim- 
mune mediated factors involved in organ transplanta- 
tion can cause similar functional and histopathological 
changes, calling the whole process chronic rejection is 
not satisfactory. As long as the result - dysfunction and 
characteristic histological changes - cannot be exclu- 
sively attributed to an alloimmune-mediated pathway, 
it is recommended to name the process CTD, leaving 
any causative factor out of consideration. 
Etiology of chronic transplant dysfunction 
In 1963, Porter et a1 reported four human cadaveric kid- 
ney allotransplants in which striking obliterative vascu- 
lar lesions developed a few months after transplantation 
[158]. All patients had experienced early episodes of 
acute rejection, and the subsequent vascular lesions 
were thought to have an immunological basis. These 
cases suggested that the process of allograft rejection 
can evolve from early acute cellular infiltration of the 
engrafted organ to a more chronic process, ultimately 
resulting in intimal arterial thickening, with interstitial 
fibrosis. However, to the present day the cause of CTD 
remains ill defined. Two working hypotheses are pro- 
posed to understand the process: 1) the phenomenon 
leading to CTD is the result of an ongoing host alloim- 
mune response. 2) Non-alloimmune responses-to-inju- 
ry, such as ischemia, can cause or aggravate the process. 
Alloantigen-specific factors 
Several data indicate that CTD is the result of the recip- 
ient’s immune response to incompatible donor tissue 
antigens. In this view, the relationships between the fol- 
lowing identified risk factors and CTD all reflect an al- 
loimmunologic mechanism: l )  Histoincompatibility, 
2) Acute rejection, 3) Suboptimal immunosuppression/ 
non-compliance, and 4) Anti-donor specific antibodies. 
Antigenic disparity in humans between donor and host 
is associated with the occurrence of CTD, as demon- 
strated in kidney, heart, and lung transplant studies. 
Long-term graft survival appeared to be strongly corre- 
lated with the degree of histocompatibility matching be- 
tween donor and recipient [67,89,146,194,214]. Cadav- 
eric kidneys with zero HLA-mismatches have a half-life 
of 13.2 years compared to 7.0 years in grafts with six-al- 
lelic mismatches [146]. Interestingly, some large unicen- 
tre studies are unable to demonstrate the benefit of his- 
tocompatibility matching for the development of CTD 
in kidneys and hearts, independently of the effect of 
acute rejection [88]. It is presently unclear whether 
matching directly affects the development of CTD or 
whether this results from a decreased incidence of acute 
rejection episodes [20,38,155,193]. 
Graft survival studies from uni- and multicentres 
alike show a strong correlation between acute rejection 
episodes and the lifespan of a graft [115,125,147,224]. 
For instance, Matas et a1 [125] showed in a group of 278 
cadaver kidney graft recipients that a single rejection 
episode in the first post-transplant year reduces the esti- 
mated graft half-life from 33 years to 22 years, whereas 
multiple rejections or a single rejection after the first 
year decreases the half-life to less than 5 years. Several 
retrospective analyses of organ grafts with CTD demon- 
strate that acute rejection is strongly related to the de- 
velopment of CTD in all types of organ transplants [17, 
28, 57,88,105,101,195]. Basadonna et a1 reported that 
in a cohort of 205 cadaveric renal transplant recipients, 
the incidence of biopsy-proven CTD was 0 YO in the 109 
patients without acute rejection, 36 YO in the 69 patients 
with an acute rejection within the first 2 months after 
transplantation ( P  < 0.001), and 63 Y in the 27 patients 
with acute rejection 60 days after transplantation 
( P  < 0.001) [45]. Other clinical studies have corroborat- 
ed and refined these findings: The onset, frequency, 
and severity of an acute rejection episode are indepen- 
dent risk factors for CTD [19,57,204,224]. Acute rejec- 
tions with complete functional recovery do not have a 
deleterious effect on the long-term outcome [39, 2261, 
whereas an increased baseline serum creatinine level af- 
ter treatment of an acute rejection episode is associated 
with CTD [92, 1471 In addition, the vascular type of 
acute rejection appears to be a stronger risk factor for 
the occurrence of CTD than interstitial rejection [223]. 
Experimental studies in kidney-, heart-, and lung trans- 
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plantation models confirm these clinical observations 
[86,90,141,232,233,235]. Nonetheless, acute rejection 
is not a prequisite for CTD: patients may also develop 
CTD without prior acute rejection episodes [41,45,54]. 
Reviewing the literature, it can be stated that at present, 
acute rejection is the most consistently identified clini- 
cal risk factor for the occurrence of CTD. 
A low dose of maintenance Cyclosporine (CsA) 
medication in some clinical studies has been associated 
with CTD [6,194,177], but not in others [68]. At 5 years 
post-transplantation, the percentage of recipients who 
were free of CTD as demonstrated by biopsy was 86% 
for those using CsA > 5 mg/kg per day versus 77 % for 
those on < 5 mg/kg per day [6]. Additional evidence 
that CTD may be related to inadequate immunosup- 
pression was provided by the histopathological studies 
of Isoniemi et a1 [96]. They found that CTD-lesions 
were less apparent in patients given protocols of triple- 
versus double-dose immunosuppressive therapy. Exper- 
imentally, we and others have demonstrated that in the 
rat aortic allograft model, both high dose CsA as well 
as other immunosuppressive agents were able to pre- 
vent the inflammatory response, and concomitantly in- 
hibit the generation of intimal lesions during the 4- 
weeks follow-up period [65,103,199]. However, in man 
it would be impossible to maintain high doses of immu- 
nosuppressants on the long-term, because of the associ- 
ated toxic side effects [203]. 
Noncompliance also indicates that CTD may result 
from inadequate immunosuppression [24,51,217]. In a 
study by the Minneapolis group, 34% patients were 
noncompliant, and this was associated with late deterio- 
ration of graft function [124]. 
Many studies have shown that following transplanta- 
tion, the majority of patients produce antibodies [49,75, 
99, 121, 122, 149, 154, 165, 168, 192, 2021. Both, pre- 
formed antibodies reactive against donor tissue, and an- 
tibodies produced after transplantation against HLA 
class I antigens and against tissue, (endothelial cells, 
smooth muscle cells) are found. A correlation between 
antibodies and CTD, however, is not consistently found 
[45, 49, 54, 58, 90, 149, 166, 1791. No difference in pan- 
el-reactive antibody levels was found between those of 
patients whose grafts were still functioning, versus those 
of patients who lost their graft due to CTD [59, 1791 
Likewise, Hosenpud et a1 found no differences in the 
presence of IgM antibodies against endothelial cells of 
kidney grafts with or without CTD [90]. Other investi- 
gators, however, observed significantly more anti-donor 
reactivity against both HLA class I and I1 in sera of pa- 
tients with biopsy-proven CTD in kidneys (94.4 YO) 
than in sera of patients with a normal functioning graft 
(12.8%) [144]. In 70% of the liver allografts with CTD, 
patients had non-HLA anti-smooth muscle and anti-nu- 
cleus antibodies, which were not present in patients with 
a healthy liver transplant [77]. 
Experimentally, Paul et al demonstrated IgG anti- 
bodies against the glomerular and tubular basement 
membrane, the mesangial cell, and endothelial cell anti- 
gens in sera of rats with a kidney allograft with CTD, 
whereas such antibodies were not found in sera from an- 
imals that had received a syngeneic graft [85, 1511. In 
other experimental models of CTD, the presence of an- 
tibodies was noted in areas with intimal hyperplasia 
[64,78]. 
Non-alloantigen associated factors 
In the late 1980-ies, attention was redrawn to the fact 
that in the pre-immunosuppression era even human kid- 
ney transplants between identical twins developed late 
morphological changes. Two-thirds of these kidney iso- 
grafts developed glomerular lesions between 2 months 
and 16 years post-transplantation, which were classified 
as a recurrence of the original disease, glomerulonephri- 
tis [69]. Two of these grafts with glomerular lesions de- 
veloped in a later stage additional vascular lesions. It 
was also suggested that such changes observed in human 
renal isografts might have been a consequence of the 
transplantation injury per se [42]. Nowadays, surgical in- 
jury and other, non-alloimmune specific factors related 
to the donor and the graft have been associated to the 
development of CTD [54, 104, 2201. These risk factors 
include: ischemia, brain death, viral infections, hyperlip- 
idemia, hypertension, age, gender, race, and the amount 
of functional tissue. 
In clinical transplantation it is still unclear if ischemia 
participates in the development of CTD. While some 
studies reported that prolonged cold ischemia reduces 
graft survival [38, 67, 2181, others found no correlation 
[153, 1551. For instance, the UNOS registry showed 
that preservation for > 24 hours significantly impaired 
late kidney graft survival rates compared to cold is- 
chemic times between 0-24 h [67]; In cardiac trans- 
plants, a prolonged ischemic time was a risk factor for 
transplant arteriosclerosis [ 131. Experimental transplant 
studies have demonstrated that ischemia per se can 
cause CTD-like lesions in the absence of allogenicity 
[225]. We [104], and others [220] have demonstrated 
that rat kidney isografts develop the same functional 
and morphological changes as allografts, including vas- 
culopathy, albeit over a much longer time interval. 
These changes appeared to be triggered mainly by is- 
chemia. Similarly, on the long-term, syngeneic aorta 
and heart transplants develop intimal hyperplasia, in 
which the degree of intimal hyperplasia correlates with 
the duration of the ischemia period [178,227]. Nonethe- 
less, it is much less clear whether the length of the is- 
chemic period plays a role in the onset of CTD in allo- 
grafted organs. While Hayry’s group showed that in re- 
nal allografts a cold ischemic time of 60 min led to in- 
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creased intimal proliferation and glomerulosclerosis, 
compared to kidneys subjected to 30 min cold ischemia 
[236], in heart and aortic allografts the duration of the 
cold ischemic period did not have an influence on the 
degree of CTD [8, 101,2271. 
It has also been suggested that in allografts the effect 
of ischemia on CTD is indirect by predisposing for acute 
rejection. Organ grafts with prolonged cold ischemia or 
with delayed graft function experience more often an 
early acute rejection episode than grafts that functioned 
immediately [72,73,145,188,218]. We showed that, fol- 
lowing 24 h of cold ischemia, increased numbers of 
CD4+ cells and macrophages infiltrated the kidney 
grafts, compared to non-ischemic controls. Importantly, 
ischemic grafts still showed significantly increased num- 
bers at one year post-transplant. Histologically, these 
grafts showed more glomerulopathy and intimal hyper- 
plasia than non-ischemic controls [104]. These data pre- 
sume a direct effect of ischemia on long-term outcome. 
The striking divergence in clinical long-term results 
between kidney grafts from cadavers and those from liv- 
ing-related and unrelated donors [212], has drawn atten- 
tion to the health of an organ before procurement. The 
hypothesis has been put forward that brain death acti- 
vates surface molecules on peripheral organs via cyto- 
kines. In brain death donors, increased serum cytokine 
levels are found before organ procurement [161]. In ex- 
perimental models of brain death, peripheral organs 
show increased endothelial cell activation [87,208] and 
a more accelerated tempo of acute rejection in organs 
from brain dead animals is observed [160,229]. The rel- 
evance for CTD still has to be proved. 
While infection with cytomegalovirus (CMV) has 
shown to be related to CTD in cardiac-, liver-, and lung 
transplantation [71, 105, 108, 128, 1431, its association 
with CTD in kidney transplants is not yet clear. A multi- 
variate analysis on risk factors for CTD performed on 
675 renal allograft recipients showed no difference in 
the incidence of CMV infection in patients who did or 
did not loose their grafts to CTD [122]. Experimentally, 
CMV infection has been identified as promotor of 
CTD in aorta, kidney and heart transplants [110, 111, 
2351. CMV infection directly affects intercellular adhe- 
sion molecule-1 (ICAM-1) expression on endothelial 
cells, [159, 2341 and induction of MHC class I1 antigens 
is observed, together with a prolonged and increased 
acute cellular infiltration of T cells and macrophages 
[109]. 
Hyperlipidemia is a controversial risk factor for al- 
lograft arteriosclerosis [18, 52, 1801. The relevance of 
hyperlipidemia in animal transplant arteriosclerosis 
models has also been a matter of controversy [3, 7, 48, 
56,133,2111. 
Systemic hypertension in clinical kidney and heart 
transplants is associated with CTD [30, 148, 157, 1621. 
In heart transplant recipients, hypertension was associ- 
ated with an earlier onset of CTD [162]. In renal al- 
lograft recipients, hypertension is a common event 
(75 %), although its role as a causative factor or a conse- 
quence of renal dysfunction is difficult to define since a 
vicious circle is created where the worsening of one pa- 
rameter leads to the worsening of the other [163]. Ex- 
perimental studies showed that systemic hypertension 
accelerates CTD in kidney allografts [106], whereas an- 
tihypertensive drugs inhibited the progression of chron- 
ic allograft dysfunction [22]. Similarly, in rat aortic 
transplants, hypertension was associated with a signifi- 
cant increase of intimal thickness, whereas ACE-inhibi- 
tion was able to decrease systolic blood pressure by 
30 YO, and concomitantly reduce intimal lesions by 40 YO 
[134]. 
Donor age is a controversial risk factor. Some investi- 
gators have found that grafts from donors over 60 years 
of age are associated with poorer survival rates [33,79, 
1231. Cardiac transplants from an older aged donor had 
an earlier onset of CTD [23,40]. 
In male recipients, solid organ grafts appeared to be 
more vulnerable for the development of CTD. In cardi- 
ac allografts, the onset of arteriosclerosis was earlier in 
males than in females [40] and the prevalence of CTD 
was reported to be higher in male- than in female recip- 
ients: 30% versus 50% free of coronary artery disease 
at 5 years ( P  = 0.01) [129]. The UNOS Transplant Reg- 
istry reported a similar observation for kidney grafts 
[67]. Experimental studies have corroborated these ob- 
servations: In rat syngeneic aorta transplants, female 
gender protects against myointimal hyperplasia [59]. 
This gender effect could reflect oestrogen. Oestrogen 
protects against cardiovascular disease, and it has been 
demonstrated that oestradiol effectively inhibits trans- 
plant arteriosclerosis in experimental models [32, 116, 
1751. 
Long-term survival of cadaveric renal transplants ap- 
peared to be related to race: Five-year graft survival 
rates were 66 YO for Asians, 61 % for Caucasians and 
Hispanics, and 47 YO for Black recipients [loo]. Black re- 
cipients of heart transplants developed CTD earlier 
than non-blacks [40]. The absence of the Duffy antigen 
Receptor for Chemokines on erythrocytes in African 
Americans seems an important risk factor for the devel- 
opment of CTD [44]. 
A risk factor reserved to the kidney is the contribu- 
tion of reduced numbers of nephrons to the progression 
of CTD. In non-transplant models in the rat, it is well es- 
tablished that kidneys with significantly reduced num- 
bers of nephrons, such as in the ‘remnant kidney model’, 
develop glomerulosclerosis, tubular atrophy, and inter- 
stitial fibrosis in response to an increased workload of 
the remaining nephrons, i. e. hyperfiltration [142, 1861. 
In a chronic kidney allograft model, Heemann et a1 
demonstrated that reduction of renal mass led to earlier 
onset of CTD and shortened survival. Moreover, iso- 
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grafts and non-transplanted, ablated kidneys having 
only 1/6 of total mass experienced proteinuria in the 
same tempo as allografts, whereas 2/6 or 3/6 nephrec- 
tomized native and isografted kidneys had negligible 
damage [83]. Thus, the reduction of functioning renal 
mass accelerated the changes characteristic for CTD, 
and after a substancial reduction, hyperfiltration plays 
an overriding role in further deterioration [117]. None- 
theless, in clinical kidney transplantantion, the signifi- 
cance of a mismatch between donor nephron supply 
and functional metabolic demand of the recipient in 
the development of CTD is unclear. Poorer survival of 
grafts from very young, elderly, black, or female donors, 
compared to grafts from donors aged 15-55, non-black 
or from male donors has been ascribed to hyperfiltra- 
tion damage [25]. None of these CTD-prone conditions, 
however, are uniformly found. Miles et a1 did not find 
that the donor kidney size was different in patients who 
lost their graft due to CTD compared with the kidney 
size of patients with stable function [135]. Others did 
not see differences in CTD between pediatric kidney re- 
cipients and adult-kidney recipients either [5]. Paired 
pediatric kidney transplantation did not improve renal 
function compared to small single pediatric kidneys 
[164]. 
Pathophysiology of chronic transplant dysfunction 
As already outlined, CTD is characterized by morpho- 
logical evidence of destruction of the transplanted organ 
[191]. The common denominator of all parenchymal or- 
gans is the development of intimal hyperplasia. Wheth- 
er the parenchymal changes with fibrosis occurs second- 
arily to gradual arterial insufficiency and ischemia, or if 
they develop from ungoing subclinical host immunolog- 
ical attacks or other factors, remains undefined. 
Immunohistochemistry of allografts with CTD has 
shown that T cells and macrophages are the predomi- 
nant graft-invading cell types, with an excess of CD4+ 
over CD8’ T cells [4, 47, 50, 82, 104, 176, 191, 1981. In- 
creased expression of adhesion molecules (ICAM-1, 
VCAM-1) [77, 1141, and MHC antigens [81, 1141 are 
seen in allografts with CTD. Also, complement and im- 
munoglobulin deposits are seen in areas with intimal hy- 
perplasia [77, 78, 90, 1141. Little consistent information 
is available on the expression of growth-regulating fac- 
tors and their receptors in organ transplants with CTD. 
An increased TGF-P expression, however, is frequently 
found [152,185,206]. 
The histologic lesions, including intimal hyperplasia, 
the infiltrating cells, upregulated adhesion molecules, 
and cytokines in organ transplants with CTD do not 
necessarily reflect an alloimmune-mediated response. 
As already mentioned, syngeneic transplants, ischemia- 
or mechanically-injured organs also show cell infiltra- 
tion, upregulation of cytokines and develop CTD-like 
lesions [104, 220, 2271. Notwithstanding, the develop- 
ment of the lesions occurs much more rapidly in allo- 
grafts, suggesting that alloimmune responses play a 
role [104]. The most consistent clinical risk factor ‘acute 
rejection’ also indirectly indicates that an alloimmune 
response is involved in CTD and suggests that CTD is, 
for the main part, the result of insufficient immunosup- 
pression. More evidence to support this hypothesis 
comes from experiments that have demonstrated that 
pretransplant immunizations with donor splenocytes ac- 
celerate CTD [41], whereas manipulations aimed at in- 
duction of tolerance delay the process [36, 1871. In the 
following subparagraphs, we suggest the route through 
which a graft may develop CTD. 
Initial response-to-injury 
Endothelial cell activation 
The specific adhesion of cells to other cells or to particu- 
lar tissues is a basic function of cell migration and recog- 
nition. Under normal conditions, contact between leu- 
kocytes and vascular endothelium is random if both 
cell types are inactive and at rest, the cells touch vessel 
walls indiscriminately. In organ transplantation, the en- 
dothelial cells are activated by ischemia, surgical manip- 
ulation, and reperfusion injury, events inherent to the 
procedure. After ischemia and reperfusion, endothelial 
cells produce oxygen free radicals predominantly via 
the xanthine-oxidase pathway, which in vitro activate 
and damage the cells [21]. Upon activation, the endo- 
thelial cells retract and release increased amounts of 
the cytokines IL-1, IL-6, IFN-y, TNF-a, the chemokines 
IL-8, macrophage chemoattractant protein (MCP)-1. 
macrophage inflammatory protein (M1P)-la and MIP- 
lp, colony stimulating factors, and multiple growth fac- 
tors such as, platelet derived growth factors (PDGF), in- 
sulin growth factor-1(IGF-1), transforming growth fac- 
tor (TGF)-P, and pro-thrombotic molecules (tissue fac- 
tor, plasminogen activator inhibitor). This secretion en- 
hances migration of neutrophils, monocytes/macro- 
phages and T lymphocytes to the site of injury [27]. 
The release of cytokines also leads to upregulation of 
adhesion molecules on the vascular endothelium [27, 
621. The proinflammatory cytokines IL-1 and TNFa in- 
duce the expression of the adhesion molecules P- and 
E-selectin on the endothelium [167, 2301, by which cir- 
culating leucocytes begin to adhere via binding to their 
surface carbohydrates [112, 127, 1971. Leucocytes are 
then triggered by the chemokines released by the endo- 
thelium, which causes upregulation of the affinity of 
the P,-integrin receptors LFA-1 and MAC-1 on their 
surface. This enables a permanent adherence of leuco- 
cytes to the endothelial adhesion molecules ICAM-1 
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and VCAM-1 [118], the expression of which is induced 
by the released cytokines IL-1P, IFNy, TNFa [26,156]. 
Activated complement also plays a role in the adhesion 
of neutrophils and monocytes to endothelium [16]. Fi- 
nally, extravasation of leucocytes occurs to the extracel- 
lular matrix and graft tissue, presumably facilitated by 
activated complement [209, 2291 and oxygen-free radi- 
cals that increase the permeability between endothelial 
cells [94]. The first cells that infiltrate the graft are neu- 
trophils. They further aggravate the inflammatory re- 
sponse through release of oxygen-free radicals and in- 
flammatory mediators, including platelet activating- 
like factors and leukotrienes. Direct evidence that oxy- 
gen free radicals, adhesion molecules, and neutrophils 
play a role in the pathogenesis of CTD is shown by inter- 
ference studies [29, 107, 2101. One recent study, for in- 
stance, revealed that carotid allografts from donor mice 
deficient in ICAM-1 had a 52 % reduction of intimal hy- 
perplasia compared to controls [183]. 
In addition to the increased expression of adhesion 
molecules on the endothelium, after reperfusion of a 
transplanted organ, a dramatic upregulaton of MHC 
class I and I1 antigens on the endothelium occurs [37, 
931, which appears to be induced by release of cytokines 
IFN-y, TNF-a and TNF-/3 [74,181]. Alterations in tissue 
density of MHC class I1 antigens are likely to influence 
the alloimmune response against the tissue [76]. Paren- 
chymal cells are also activated after ischemia. In non- 
transplanted kidneys, MHC class I and I1 antigens are 
upregulated on the tubular epithelium [93,189]. Epithe- 
lial cells in lung autotransplants showed a mild expres- 
sion of MHC class I1 after cold ischemia [181]. 
CD4' T-lymphocytes infiltrate ischemic allografts, 
isografts and non-transplanted organs [ l l ,  93, 104, 
2201. In addition, T cell associated cytokines, such as 
IFN-y and TNF-a are produced [93] and blockade of 
the C28-B7 costimulatory pathway decreased early in- 
flux of T cells and expression of T cell associated cyto- 
kines [207]. We showed that cyclosporine was able to 
overcome the deleterious effects of ischemia in synge- 
neic transplants with a concomitant decrease in infil- 
trating CD4' T-cells [104]. The role of CD4' T-lympho- 
cytes in ischemia has been elegantly demonstrated. In 
a liver ischemia model, CD4' T cell deficient mice had 
significantly less hepatic damage [236]. This response 
to ischemic injury is initially independent from alloge- 
nicity: Heemann et al have demonstrated that the pat- 
tern of cellular infiltration and cytokine expression in 
both syngeneic and allogeneic cardiac grafts was similar 
if not identical within the first 48-72 h after engraft- 
ment [84]. Thus, as result of the transplant procedure, 
a complete network of cytokines is already activated, 
even before allogeneic reactions develop. Some pre- 
transplant conditions of both donor and recipient, as 
discussed in the etiology section, appear to aggravate 
this initial injury. 
Alloimmune response 
The recognition of histoincompatible MHC alloanti- 
gens will provoke an alloimmune response. Class I anti- 
gens, constitutively expressed on nucleated cells, inter- 
act with CD8' cells, and class I1 antigens, constitutively 
expressed on lymphoid cells and inducible on endothe- 
lial cells, macrophages and fibroblasts are recognised 
by CD4' cells. Intact foreign MHC molecules on donor 
cells may be directly recognised by T cells, either in 
combination with an allopeptide or a selfpeptide, which 
results in an exceptionally strong immune response. 
Frequencies of T cell precursors that respond to alloan- 
tigens are 10-100 fold higher than for other nominal an- 
tigens [182]. In draining lymph nodes and spleen, allore- 
active T-cells recognise donor MHC indirectly, present- 
ed by self-MHC molecules on recipient antigen present- 
ing cells [190]. 
In allorecognition, the MHC antigen is bound to the 
T cell receptor. For activation of T-cells, costimulatory 
pathways as the CD28 receptor on T cells with its ligand 
B7, and CD40 with its T-cell based ligand, CD40L are 
mandatory for the promotion of T-cell effector function 
and proliferation. The adhesion molecules ICAM-1, 
VCAM-1 and LFA-3 have also been shown to co-stimu- 
late T cell activation. Once the CD4' T cell is activated, 
a cascade of events amplifies the alloimmune response: 
Secreted IL-2 leads to clonal proliferation of alloreac- 
tive cells and stimulates CD8' T cells to develop into 
mature cytotoxic effector cells. Release of cytokines 
such as IFNy and TNFa may further increase the ex- 
pression of adhesion molecules, and MHC antigens on 
the endothelium, smooth muscle cells and parenchymal 
cells. IFNy is also responsible for the activation of mac- 
rophages, which together with CD8' cells are cytotoxic 
to the graft cells, leading to acute graft failure, when no 
immunosuppressive intervention is given to prevent or 
to overcome this CD4' T-cell mediated alloimmune re- 
sponse. 
Despite inhibition of T cell activation by cyclospo- 
rine, FK 506, or anti-112 monoclonal antibodies, these 
therapies do not prevent the development of CTD in 
clinical transplantation, probably due to too low doses 
of these drugs. In experimental models, continuously 
high doses of cyclosporin A or blockade of CD28/B7 
and CD40KD40L costimulatory pathways decrease 
early infiltration and almost completely inhibit intimal 
hyperplasia in murine aortic and cardiac allografts [65, 
171,199,2051. Evidence that the CD4' Tcell is involved 
in the genesis of intimal hyperplasia is elegantly exem- 
plified by Shi et al: Carotid allografts in mice that were 
genetically deficient for the CD4 + T cell developed in- 
timal thickening to only 40% of that seen in controls 
[184]. 
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Anti-donor specific antibodies 
The cytokines IL-4, IL-6, and IL-10 released by activat- 
ed CD4’ cells are growth- and differentiation factors 
for B cells. Activation of B cells may result in matura- 
tion into plasma cells with allospecific antibody produc- 
tion. Since immunoglobulin, complement, and antigen- 
antibody complexes have been found in areas of intimal 
hyperplasia [15, 170, 2161, humoral activity has long 
been thought to be primarily responsible for CTD. A re- 
cent finding of upregulated immunoglobulin J chain in 
arteriosclerotic lesions suggests the presence of IgM- or 
IgA-producing plasma cells in such grafts [31]. Donor- 
specific antibodies are found against HLA antigens, en- 
dothelial cells, mesangial cells, glomerular and tubular 
basement membrane, smooth muscle cells and the nu- 
cleus [99,201]. 
The precise significance of antibody deposition that 
mitigates over time, as shown in many animal models 
[64, 77, 781, remains to be established. In experiments 
with SCID mice, which lack T and B cell mediated cellu- 
lar responses, passive transfer of anti-donor specific an- 
tibody was sufficient to produce graft arteriosclerosis 
with a perivascular mononuclear cell infiltrate in long- 
standing cardiac allografts [174]. While some investiga- 
tors found that the degree of intimal hyperplasia aortic 
and cardiac allografts in mice recipients with a defect 
of humoral antibody production was comparable to 
that seen in immunocompetent mice [34], Russell et a1 
showed that cardiac allografts in B cell deficient mice 
did not develop fibroproliferative arteritis [173]. These 
investigators also demonstrated that in two donor-recip- 
ient mice combinations in which anti-donor antibodies 
are generally undetectable, intimal fibrosis was uncom- 
mon, whilst these recipients became capable of produc- 
ing fibrous lesions in allografted hearts when given 
anti-donor, class I antibody [173]. Similarly to Russell’s 
report, Shi et al showed that CD4’ cells, humoral anti- 
bodies and macrophages together were necessary for in- 
timal hyperplasia in a mouse carotid allograft model. 
Arteries allografted into mice, deficient in both T cell 
receptors and humoral antibody, showed almost no neo- 
intimal proliferation, whereas those grafted into mice, 
deficient only in humoral antibody, developed minimal 
intimal hyperplasia [184]. 
The mechanism by which antibodies contribute to 
CTD is rather speculative. One recent study has shown 
that anti-HLA antibodies, when attached to their HLA 
class I antigen on cultured endothelial cells, induce in- 
creased gene expression of bFGF receptor and ligand 
binding, and a 4-6 fold cell proliferation, as it does for 
smooth muscle cells [go]. Marsh et a1 hypothetized that 
IgG induces the accumulation, differentiation and sub- 
sequent cytokine production by intimal macrophages 
via crosslinking of FcyR thereby preventing apoptosis 
of monocytes. FcyR crosslinking induces the production 
of MCP-1 and IL-8, which can promote both macroph- 
age and lymphocyte accumulation [119,120]. 
Chronic response-to-injury 
It is not clear why this response to the initial injury does 
not disappear over time, as seen in normal healing pro- 
cesses. In allografts, it is conceivable that the alloanti- 
gens are responsible for an ongoing cellular and/or hu- 
moral response. T cells decline to relatively low num- 
bers as the process enters its chronic phase, they and 
their products may continue to provide a persisting low 
grade immunological response and ongoing subclinical 
injury to the graft’s endothelium and parenchyma over 
time [221]. Since there is a continuous supply of donor 
allopeptides processed and presented by host profes- 
sional APCs (dendritic cells, macrophages, B cells), 
self-MHC restricted T cells may perpetuate a chronic al- 
loimmune response. Suciu-Foca and collaborators dem- 
onstrated a persistent allopeptide reactivity in patients 
developing CTD [35, 2011. The continued alloimmune 
recognition in long term graft recipients is evidenced 
by the presence of graft reactive cytotoxic T splenocytes 
in long term recipients of cardiac allografts. Anti-donor 
specific antibodies may also maintain a chronic alloim- 
munologic injury: Donor reactive alloantibodies in the 
recipient’s circulation have been demonstrated long- 
term after engraftment [149,228]. 
The significance of donor alloantigens on ‘non-pro- 
fessional’ antigen presenting cells, like the endothelial 
cells for T cell recognition is unclear. An indication that 
donor MHC class I and I1 antigens play a role in the 
chronic phase has recently been obtained. Carotid allo- 
grafts from donor mice deficient in MHC I1 molecules 
showed a reduction of intimal hyperplasia formation of 
33 %, primarily due to a reduction in smooth muscle 
cell accumulation [183]. The absence of such a continu- 
ous alloantigeneic stimulus in syngeneic transplants 
might explain the much more rapid development of 
CTD in allografts. 
Thus, the strength of the initial trigger, the length of 
the trigger, and the presence of additional factors, and 
under which alloantigens, determine the onset and the 
pace of progress of irreversible chronic lesions 
Macrophages 
Activated T cells produce, amongst others, the cytokine 
RANTES (Regulated upon activation, normal T cell ex- 
pressed and secreted), a macrophage chemoattractant 
[137]. Other cytokines, such as IL-8, MCP-1 and osteo- 
pontin released by interstitial cells and smooth muscle 
cells are chemotactic for macrophages as well. Upregu- 
lated adhesion molecules contribute to their localisation 
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in areas of injury. Macrophages invade the graft and be- 
come activated by IFN-y. The continuous presence, the 
activated state, and the upregulation of macrophage as- 
sociated cytokines in long-term allografts with CTD 
and, in other chronic diseases, with fibrotic features, 
suggest a pivotal role for the macrophages [12,172,198]. 
The importance of macrophages was demonstrated 
by the prevention of CTD by treatment with gammalac- 
tone, a synthetic inhibitor of macrophage activity, in a 
rat renal allograft model [12], and by the observation 
that carotid allografts in mice deficient in macrophages, 
developed only slight intimal hyperplasia [184]. Activat- 
ed macrophages produce a number of cytokines includ- 
ing TNF-a, IL-lP, PDGF, bFGF, and TGF-P. This per- 
petuates and amplifies the fibrogenic signals. 
Cytokines and growth factors 
Cytokines and growth factors play an important role in 
the chronic phase. They have profound effects on cells 
of the graft and on the immune system. Cytokines and 
growth factors are pleiotropic, with biological effects 
on many cell subpopulations, are, furthermore, regulat- 
ed via autocrine, paracrine or systemic pathways, and 
there is a great deal of redundancy in the cytokine net- 
works. The advent of the transgenic and knock-out tech- 
nology has allowed dissecting of the molecular pathways 
causally involved in allograft arteriosclerosis [200]. No 
cytokine has been unequivocally identified as specific 
to alloimmune response. 
The redundancy of the cytokine system has been 
stressed by gene knockout technology: IL-4 is not neces- 
sary for the development of graft coronary arterioscle- 
rosis, nor does its absence appear to augment the devel- 
opment of vascular lesions. In addition, TNFa-R1 defi- 
ciency in either donor heart or recipient does not abro- 
gate the development of graft arteriosclerosis [140]. 
The increased expression of TGF-PI has been linked to 
transplant arteriosclerosis both by clinical and experi- 
mental studies, and transfection of TGF-/3 to the kidney 
led to increased accumulation of the extracellular ma- 
trix and glomerulosclerosis [95]. Interestingly, cardiac 
allografts in TGFP, deficient recipients developed sig- 
nificantly more intimal hyperplasia than controls [102]. 
In 1989, IFN-y has already been postulated by Libby 
et a1 to play a central role in CTD because of its effects 
on T cells and macrophages, as outlined above [113]. 
The availabilty of IFN-y deficient mice permitted this 
group to test critically the contribution of IFN-y to the 
development of CTD [138, 1391. Cardiac allografts in 
IFN-y deficient mice developed only minimal or no 
transplant arteriosclerosis as compared to controls. In 
addition, similar results on graft arteriosclerosis were 
found after the administration of IFN-y neutralizing an- 
tibody in normal rats. 
Chronic remodelling 
The process eventually becomes irreversible, but the pe- 
riod in which this occurs is variable: Retransplantation 
of allogeneic kidney grafts back into the original donor 
strain prevents CTD, when the retransplant is perform- 
ed within 12 weeks, but not after this period [219]. In 
aorta- and cardiac allografts Mennander et a1 and Izu- 
tani et a1 reported a much shorter time interval after 
which intimal hyperplasia continues, when the graft 
was transplanted back into the donor strain [97,132]. 
Smooth muscle cells 
Once the endothelial cells are injured, the secreted cyto- 
kines, i.e. IL-1, PDGF, IGF-1, TGF-P and bFGF, and 
metabolic products such as prostaglandin, nitric oxide, 
and oxidized low-density lipoproteins induce smooth 
muscle cell (SMC) proliferation, as reviewed by Ross 
[169]. Activated T cells and macrophages, often in close 
anatomical association with the replicating SMC, pro- 
duce also a whole wealth of these factors. Platelets de- 
posited along the injured vascular wall contribute by se- 
creting PDGF, EGF, TGF-/3 and tromboxane-A,. When 
SMC migrate to the intima, they transform their pheno- 
type from ‘contractile’ to ‘secretory’ and the cells be- 
come capable of replication [169, 2151. In addition, 
SMC can produce many of these growth factors and 
may generate similar autocrine or paracrine loops of 
stimulation for cell replication, as seen in ‘classical’ ath- 
erosclerosis [169]. These factors also may modulate ex- 
tracellular matrix synthesis, angiogenesis, and leucocyt 
adhesion. Moreover, activated SMC can express MHC 
class I and I1 and may act as antigen presenting cells. 
Numerous drugs inhibit SMC proliferation, and some, 
such as angiopeptin, have been shown to be of benefit 
in organ allografts [55,130,131]. 
Extracellular matrix 
As the endothelium is damaged, the underlying extra- 
cellular matrix can become activated and act as costimu- 
lator for leucocytes to facilitate recruitment and ex- 
travasation. For instance, exposed collagens and fi- 
bronectin may act as costimulators for activated CD4’ 
T-cells [43, 1261. After activation by antigens, T cells 
synthesize heparanase, which facilitates migration 
through tissue [61]. The cleavage of heparan sulphate 
by this enzyme also activates and releases fibrogenic 
growth factors, such as basic fibroblast growth factor in 
the extracellular matrix [66]. TGF-P, produced by the 
activated T cells and macrophages, stimulates the pro- 
duction of ECM molecules and inhibits the matrix de- 
grading enzymes. The thickening of basal membranes, 
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such as that of the pericapillary and glomerular endo- 
thelium in the transplanted kidney, interstitial fibrosis 
and sclerosis, and in intima hyperplasia smooth muscle 
cell proliferation is accompanied by excessive synthesis 
of connective tissue proteins. 
Conclusion 
CTD is currently the main cause of late graft failure. It is 
usually associated with previous acute rejection epi- 
sodes, although several non-alloantigen-associated fac- 
tors, like ischemia, hyperlipedimia, and hypertension 
may enhance the process. We propose that the process 
leading to CTD in allografts begins at the time of graft 
retrieval, is enhanced by ischemic injury, which pro- 
vokes an alloimmune response to the endothelial cells, 
the extracellular matrix and parenchyma. An ongoing 
alloimmune response, in which several non-alloimmune 
factors may interfere, eventually leads to irreversible le- 
sions of the graft. 
References 
1. Abbasoglu 0, Levy MF, Brkic BB, 
Testa G, Jeyarajah DR, Goldstein 
RM, Husberg BS, Gonwa TA, Klint- 
malm GB (1997) Ten years of liver 
transplantation: an evolving under- 
standing of late graft loss. Transplan- 
tation 64: 1801-1807 
2. Abu-Elmagd KM, Tzakis A, Todo S ,  
Reyes J, Fung J, Nakamura K, Wright 
H, Furukawa H, Demetris J, Van Thiel 
DH, Starzl T E  (1993) Monitoring and 
treatment of intestinal allograft rejec- 
tion in humans. Transplant Proc 25: 
1202-1203 
Hypercholesterolemia does not exac- 
erbate arterial intimal thickening in 
chronically rejecting rat cardiac allo- 
grafts. Transplant Proc 21: 437439 
4. Adams DH, Russell ME, Hancock 
WW, Sayegh MH, Wyner LR, Kar- 
novsky MJ (1993) Chronic rejection in 
experimental cardiac transplantation: 
studies in the Lewis-F344 model. Im- 
munol Rev 134: 5-19 
5. al-Bader W el-R, Landsberg D, Man- 
son AD, Levin A (1996) Renal func- 
tion changes over time in adult recipi- 
ents of small pediatric kidneys. Evi- 
dence against hyperperfusion injury. 
Transplantation 62: 611-615 
6. Almond PS, Matas AJ, Gillingham KJ 
Dunn DL, Payne WD, Gores P, 
Gruessner R, Najarian JS (1993) Risk 
factors for chronic rejection in renal 
allograft recipients. Transplantation 
3. Adams DH, Karnovsky MJ (1989) 
55: 7.52-757 
7. Alonso DR, Storek PK, Minick R 
(1977) Studies on the pathogenesis of 
atherosclerosis induced in rabbit car- 
diac allografts by the synergy of graft 
rejection and hypercholesterolemia. 
Am J Pathol87: 415-442 
8. Andersen He), Holm P, Stender S ,  
Hansen BF, Kjeldsen K, Nordestgaard 
BG (1995) Relative importance of is- 
chemic injury and immunological in- 
jury on the development of transplant 
arteriosclerosis in rabbit aortic allo- 
grafts. Transplantation 60: 631-638 
9. Annual Report 1998 of Eurotrans- 
plant Foundation: preliminary data 
10. Annual report: UNOS 1996, Annual 
Report of the U. S. Scientific Registry 
of Transplant Recipients and the Or- 
gan Procurement and Transplantation 
Network 
11. Azuma H, Nadeau K, Takada M, 
Mackenzie HS, T h e y  NL (1997) Cel- 
lular and molecular predictors of 
chronic renal dysfunction after initial 
ischemia/reperfusion injury of a single 
kidney. Transplantation 64: 190-197 
12. Azuma H, Nadeau KC, Ishibashi M, 
Tilney NL (1 995) Prevention of func- 
tional, structural, and molecular chan- 
ges of chronic rejection of rat renal al- 
lografts by a specific macrophage in- 
hibitor. Transplantation 60: 1577-1582 
13. Baan CC, Holweg CTJ, Niesters 
HGM, Van Gelder T, Mol WM, 
Mochtar B, Balk AHMM, Weimar W 
(1997) Intragraft cytokine and growth 
factor mRNA expression in relation to 
graft vascular disease after heart 
transplantation. Transplant Proc 29: 
14. Backman L, Gibbs J, Levy M, McMil- 
lan R, Holman M, Husberg B, Gold- 
stein R, Gonwa TA, Klintmalm G 
(1993) Causes of late graft loss after 
liver transplantation. Transplantation 
55: 1078-1082 
15. Baldwin WM 111, Hutchinson IF, Mei- 
jer CJ, Tilney NL (1981) Immune re- 
sponses to allografts. Marked decrease 
in medullary thymocytes and splenic T 
lymphocytes after cyclosporin A treat- 
ment. Transplantation 31: 117-120 
2529-2530 
16. Baldwin WM, Pruitt SK, Brauer RB, 
Daha MR, Sanfilippo F (1995) Com- 
plement in organ transplantation. 
Transplantation 59: 797-808 
17. Bando K, Paradis IL, Similo S ,  Konishi 
H,  Komatsu K, Zullo TG, Yousem SA, 
Close JM, Zeevi A, Duquesnoy RJ, 
et a1 (1995) Obliterative bronchiolitis 
after lung and heart-lung transplanta- 
tion. An analysis of risk factors and 
management. J Thorac Cardiovasc 
Surg 110: 4-13 
18. Barbir M, Kushwha S ,  Hunt B, Mac- 
ken A, Thompson GR, Mitchell A, 
Robinson D, Yacoub M (1992) Lipo- 
protein (a) and accelerated coronary 
artery disease in cardiac allograft re- 
cipients. Lancet 340: 1500-1502 
19. Basadonna GP, Matas AJ, Gillingham 
KJ, Payne WD, Dunn DL, Sutherland 
DE,  Gores PF, Gruessner RW, Najari- 
an JS (1993) Early versus late acute 
renal allograft rejection: impact on 
chronic rejection. Transplantation 55: 
993-995 
20. Beckingham IJ, Dennis MJS, Bishop 
MC, Blarney MC, Smith SJ, Nicholson 
ML (1994) Effect of human leucocyte 
antigen matching on the incidence of 
acute rejection in renal transplanta- 
tion. Br J Surg 81: 574-577 
21. Beetsch JW, Park TS, Dugan LL, Shah 
AR, Gidday JM (1998) Xanthine oxi- 
dase-derived superoxide causes reoxy- 
genation injury of ischemic cerebral 
endothelial cells. Brain Res 786: 89-95 
22. Benediktsson H, Chea R, Davidoff A, 
Paul LC (1996) Antihypertensive drug 
treatment in chronic renal allograft 
rejection in the rat. Effect on structure 
and function. Transplantation 62: 
1634-1642 
23. Bieber CP, Hunt SA, Schwinn DA, Ja- 
mieson SA, Reitz BA, Oyer PE, 
Shumway NE, Stinson BE (1981) 
Complications in long term survivors 
of cardiac transplantation. Transplant 
Proc 13: 207-211 
395 
~ ~ 
24. Bittar AE, Keitel E, Garcia CD, Bru- 
no RM, Silviera AE, Messias A, Gar- 
cia VD (1992) Patient non-compliance 
as a cause of late kidney graft failure. 
Transplant Proc 24: 2720-2721 
25. Brenner BM, Cohen RA, Milford EL 
(1992) In renal transplantation, one 
size may not fit all. JASN 3: 162-169 
(1992) Effects of tumor necrosis factor, 
lipopolysaccharide, and IL-4 on the 
expression of vascular endothelial cell 
adhesion molecule-1 in viva Correla- 
tion with CD3 + T cell infiltration. 
J Immunol149: 2954-2960 
27. Briscoe DM, Schoen FJ, Rice GE, 
Bevilacqua MP, Ganz P, Prober JS 
(1991) Induced expression of endo- 
thelial-leucocyte adhesion molecules 
in human cardiac allografts. Trans- 
plantation 51: 537-539 
28. Brunner-La Rocca HP, Schneider J, 
Kunzli A, Turina M, Kiowski W (1998) 
Cardiac allograft rejection late after 
transplantation is a risk factor for graft 
coronary artery disease. Transplanta- 
tion 65: 53843 
29. Buerke M, Prufer D, Dahm M, Oelert 
H,  Meyer J, Darius H (1998) Blocking 
of classical complement pathway in- 
hibits endothelial adhesion molecule 
expression and preserves ischemic 
myocardium from reperfusion injury. 
J Pharmacol Exp Ther 286: 429-438 
30. Cheigh JS, Haschemeyer RH, Wang 
JC, Riggio RR, Tapia L, Stenzl KH, 
Rubin AL (1989) Hypertension in 
kidney transplant recipients. Effect on 
long-term renal allograft survival. Am 
J Hypertens 2: 341-348 
31. Chen J, Myllarniemi M, Akyurek LM, 
Hayry P, Marsden PA, Paul LC (1996) 
Identification of differently expressed 
genes in rat aortic allograft vasculopa- 
thy. Am J Pathol149: 597-611 
32. Cheng LP, Kuwahara M, Jacobsson J, 
Foegh ML (1991) Inhibition of myoin- 
timal hyperplasia and macrophage in- 
filtration by oestradiol in aorta allo- 
grafts. Transplantation 52: 967-972 
33. Chertow GM, Milford EL, Mackenzie 
HS, Brenner BM (1996) Antigen-in- 
dependent determinants of cadaveric 
kidney transplant failure. JAMA 276: 
26. Briscoe DM, Cotran RS, Pober JS 
1732-1736 
34. Chow LH, Huh S, Jiang J, Zhong R, 
Pickering JG (1996) Intimal thicken- 
ing develops without humoral immu- 
nity in a mouse aortic allograft model 
of chronic vascular rejection. Circula- 
tion 94: 3079-3082 
35. Ciubotariu R, Liu Z, Colovai AI, Ho 
E, Itescu S, Ravalli S, Hardy MA, 
Cortesini R,  Rose EA, Suciu-Foca N 
(1998) Persistent allopeptide reactivity 
and epitope spreading in chronic re- 
jection of organ allografts. J Clin In- 
vest 101: 398-405 
36. Colson YL, Zadach K, Nalesnik M, 
Ildstad ST (1995) Mixed allogeneic 
chimerism in the rat -donor-specific 
transplantation tolerance without 
chronic rejection for primarily vascu- 
larized cardiac allografts. Transplanta- 
tion 6 0  971-980 
37. Colvin RB (1990) Cellular and molec- 
ular mechanisms of allograft rejection. 
Ann Rev Med 41: 361-375 
38. Connolly J, Dyer P, Martin S, Parrott 
N, Pearson R, Johnson R (1996) Im- 
portance of minimizing HLA-DR 
mismatch and cold preservation time 
in cadaveric renal transplantation. 
Transplantation 61: 709-714 
ME, Henry ML, Elkhammas EA, Da- 
vies EA, Bumgardner GL, Ferguson 
RM (1997) Impact of acute rejection 
and early allograft function on renal 
allograft survival.Transp1antation 63: 
1611-161 5 
40. Costanzo MR, Naftel DC, Pritzker 
MR, Heilman JK 3rd, Boehmer JP, 
Brozena SC,Dec GW, Ventura HO, 
Kirklin JK, Bourge RC, Miller LW 
(1998) Heart transplant coronary ar- 
tery disease detected by coronary an- 
giography: a multiinstitutional study of 
preoperative donor and recipient risk 
factors. Cardiac Transplant Research 
Database. J Heart Lung Transplant 17: 
744-753 
41. Cramer DV, Chapman FA, Wu GD, 
Harnaha JB, Qian SQ, Makowka L 
(1990) Cardiac transplantation in the 
rat. 11. Alteration of the severity of 
donor graft arteriosclerosis by modu- 
lation of the host response. Transplan- 
tation 50: 554-558 
42. Dammin GJ (1966) Renal transplant: 
correlations of histological patterns 
with function in the kidney. In: Mostofi 
FK, Smith D E  (eds) The Kidney. Wil- 
liams and Wilkins, pp 445468 
43. Dang NH, Torimoto Y, Schlossman S, 
Morimoto C (1990) Human 
CD4 helper T cell activation: function- 
al involvement of two distinct collagen 
receptors, IF7 and VLA integrin fami- 
ly. J Exp Med 172: 649-652 
44. Danoff TM, Hallows KR, Burns JE, 
Brayman KL, Feldman HI (1999) Re- 
nal allograft survival in African- 
Americans: Influence of the Duffy 
blood group. Transplantation 67:SX 
39. Cosio FG, Pelletier RP, Falkenhain 
45. Davenport A, Younie ME, Parsons 
JEM, Klouda PT (1994) Development 
of cytotoxic antibodies following renal 
allograft transplantation is associated 
with reduced graft survival due to 
chronic vascular rejection. Nephrol 
Dial Transplant 9: 1315-1319 
46. Deligeorgi-Politi H, Wight DG, Calne 
RY (1994) Chronic rejection of liver 
transplants revisited. Transpl Int 7: 
442-447 
47. Diamond JR, Tilney NL, Frye J, Ding 
G, McElroy J, Pesek-Diamond I, Yang 
H (1992) Progressive albuminuria and 
glomerulosclerosis in a rat model of 
chornic renal allograft rejection. 
Transplantation 54: 710-716 
48. Dimeny E, Fellstrom B, Larsson E, 
Tufveson G, Lithell H (1993) Hyper- 
lipoproteinemia in renal transplant re- 
cipients: is there a linkage with chronic 
rejection? Transplant Proc 25: 
2065-2066 
49. Dubel L, Farges 0, Johanet C, Sebagh 
M, Bismuth H (1998) High incidence 
of anti-tissue antibodies in patients ex- 
periencing chronic liver allograft re- 
jection. Transplantation 65: 1072-1075 
50. Duijvestein AM, Van Breda Vriesman 
PJC (1991) Chronic renal allograft re- 
jection. Selective involvement of the 
glomerular endothelium in humoral 
immune reactivity and intravascular 
coagulation. Transplantation 52: 
51. Dunn J, Golden D, Van Buren CT, 
195-202 
Lewis RM, Lawen J, Kahan BD (1990) 
Causes of graft loss beyond two years 
in the cyclosporine era. Transplanta- 
tion 49: 349-353 
52. Escobar A, Ventura HO, Stapleton 
DD, Mehra MR, Ramee SR, Collins 
TJ, Jain SP, Smart FW, White CJ 
(1994) Cardiac allograft vasculopathy 
assessed by intravascular ultrasonog- 
raphy and nonimmunologic risk fac- 
tors. Am J Cardiol74: 1042-1046 
53. Fangman J, Fruhauf N, Oldhafer K, 
Offner G (1999) Living related and 
cadaveric kidney transplantation- 
What are the major differences? 
Transpl Proc 31: 203-204 
54. Fellstrom B, Akyiirek ML, DimCny E, 
Kaijser M, Larsson E, Wanders A, 
Wahlberg J (1996) Nonimmunological 
factors involved in long-term renal al- 
lograft deterioration. Adv Nephrol 
Necker Hosp 25: 51-62 
55. Fellstrom B, Dimeny E, Foegh ML, 
Larsson E, Wanders A, Tufveson G 
(1991) Accelerated atherosclerosis in 
heart transplants in the rat simulating 
chronic vascular rejection: effects of 
prostacyclin and angiopeptin. Trans- 
plant Proc 23: 525-528 
396 
56. Fellstrom B, Dimeny E, Larsson E, 
Claesson K, Tufveson G (1990) Rap- 
idly proliferating arteriopathy in cy- 
closporin-induced permanently sur- 
viving rat cardiac allografts simulating 
chronic vascular rejection. Clin Exp 
Immunol80: 288-292 
57. Ferguson R (1994) Acute rejection 
episodes - Best predictor of long-term 
primary cadaveric renal transplant 
survival. Clin Transplanation 8: 
328-331 
58. Ferry BL, Welsh KI, Dunn MJ, Law D, 
Proctor J, Chapel H, Yacoub MH, 
Rose ML (1997) Anti-cell surface en- 
dothelial antibodies in sera from car- 
diac and kidney transplant recipients: 
association with chronic rejection. 
Transpl Immunol5: 17-24 
Ramwell P (1995) Gender effects on 
myointimal hyperplasia. Transpl Proc 
59. Foegh M, Rego A, Lou H, Katz N, 
27: 2 0 7 ~ ~ 0 7 2  
60. Freese DK, Snover DC, Sharp HL, 
Gross CR, Savick SK, Payne WD 
(1991) Chronic rejection after liver 
transplantation: a study of clinical, 
histopathological and immunological 
features. Hepatology 13: 882-891 
61. Fridman R, Lider 0, Napaestek, Fuks 
Z ,  Vlodavsky I, Cohen IR (1987) Sol- 
uble antigen induces T lymphocytes to 
secrete an endoglycosidase that de- 
grades the heparan sulphate moiety of 
subendothelial extracellular matrix. 
J Cell Physiol130 85-92 
62. Fuggle S, Sanderson JB, Gray DWR, 
Richardson A, Morris PJ (1993) Vari- 
ation in expression of endothelial ad- 
hesion molecules in pretransplant and 
transplanted kidneys - correlation 
with intragraft events. Transplantation 
63. Gao SZ, Schroeder JS, Alderman EL, 
Hunt SA, Silverman JF, Wiederhold V, 
Stinson EB (1987) Clinical and labo- 
ratory correlates of accelerated coro- 
nary disease in the cardiac transplant 
patient. Circulation 76:V56-61 
64. Geerling RA, Ansari AA, Lafond- 
Walker AM, Baumgartner WA, Her- 
skowitz A (1998) Accelerated arterio- 
sclerosis in aortic grafts: a role for ac- 
tivated complement and IgM antibody 
in early lesion development. Trans- 
plant Proc 30: 1017-1019 
65. Geerling RA, De Bruin RWF, Sche- 
ringa M, Bonthuis F, Jeekel J, IJzer- 
mans JNM, Marquet RL (1994) Sup- 
pression of acute rejection prevents 
graft arteriosclerosis after allogeneic 
aorta transplantation in the rat. Trans- 
plantation 58: 1258-1263 
55: 117-123 
66. Gilat D, Cahalon L, Hershkoviz R, 
Lider 0 (1996) Interplay of Tcells and 
cytokines in the context of enzymati- 
cally modified extracellular matrix. 
Immunology Today 17: 16-20 
67. Gjertson DW (1996) A multi-factor 
analysis of kidney graft outcomes at 
one and five years posttransplantation: 
1996 UNOS update. In: Cecka JM, 
Terasaki PI (eds) Clinical Transplants. 
UCLA Tissue Typing Laboratory, Los 
Angeles, California, pp 343-360 
68. Gjertson DW (1991) Survival trends in 
long-term first cadaver-donor kidney 
transplants. In: Terasaki P (ed) Clini- 
cal Transplant. UCLA Tissue Typing 
Laboratory, Los Angeles, CA, 
pp 225-235 
69. Glassock RJ, Feldman D, Reynolds 
ES, Dammin GJ, Merrill JP (1968) 
Human renal isografts: a clinical and 
pathologic analysis. Medicine 47: 
411454 
70. Grant D (1996) Current results of in- 
testinal transplantation. Lancet 347: 
1801-1803 
71. Gratton MT, Moreno-Cabral CE, 
Starnes VA, Oyer PE, Stinson EB, 
Shumway NE (1989) Cytomegalovirus 
infection is associated with cardiac al- 
lograft rejection and atherosclerosis. 
72. Grinyo JM, Gil-Vernet S, Moreso F, 
Seron D, Fulladosa X, Cruzado JM, 
Riera L, Anunciada AI, Hueso M, Al- 
sina J (1997) Ischemia-reperfusion in- 
jury as a risk factor for late kidney 
graft failure. In: Touraine JL, Trae- 
ger J, BCtuel H, Dubernaed JM, Re- 
villard JP, Dupuy C (eds) Late graft 
loss. Kluwer Academic, London, 
73. Halloran PF, Aprile M, Farewell V 
JAMA 261: 3561-3566 
pp 77-83 
(1998) Early function as the principal 
correlate of graft survival. Transplan- 
tation 46: 223-228 
74. Halloran PF, Cockfield SM, Madrenas 
AJ (1989) The mediators of inflam- 
mation (interleukin-1, Interferon-y, 
and Tumor necrosis factor) and their 
relevance to rejection. Transplant Proc 
75. Halloran PF, Schlaut J, Solez K, Srini- 
vasa NS (1992) The significance of anti 
class I response. Clinical and patho- 
logical features of renal transplants 
with anti class I antibody. Transplanta- 
tion 53: 550-555 
76. Halloran PF, Wadgymar A, Autenried 
P (1986) The regulation of expression 
of major histocompatibility complex 
products. Transplantation 41: 413-420 
21: 26-30 
77. Hancock WH, Whitley WD, Tullius 
SG, Heemann UW, Wasowska B, 
Baldwin WM 111, Tilney NL (1993) 
Cytokines, adhesion molecules, and 
the pathogenesis of chronic rejection 
of rat renal allografts. Transplantation 
56: 643-650 
78. Hancock WW, Shi C, Picard MH, Bi- 
anchi C, Russell ME (1995) LEW-to- 
F344 carotid artery allografts: analysis 
of a rat model of posttransplant vascu- 
lar injury involving cell-mediated and 
humoral responses. Transplantation 
79. Hariharan S, Mcbride MA, Bennett 
60: 1565-1572 
LE, Cohen EP (1997) Risk factors for 
renal allograft survival from older ca- 
daver donors. Transplantation 64: 
80. Harris PE. Bian H. Reed EF (1997) 
1748-1754 
81 
Induction of high affinity fibroblasi 
growth factor receptor expression and 
proliferation in human endothelial 
cells by anti-HLA antibodies: a possi- 
ble mechanism for transplant athero- 
sclerosis. J Immunoll59: 5697-5704 
Hayry P, Mennander A, Yilmaz S, 
Ustinov J, Raisanen A,Miettinen A, 
Lautenschlager I, Lemstrom K, 
Bruggeman CA, Paavonen T (1 992) 
Towards understanding the patho- 
physiology of chronic rejection. Clin 
Invest 70: 780-790 
82. Hayry P, Yilmaz S, Lemstrom K, Ko- 
skinen P, Raisanen-Sokolowski A, 
Mennander A, Krogerus L, Taskinen 
E, Paavonen T, Myllarniemi M, Kallio 
E, Aaavik E, Alatalo S, Isoniemi H 
(1996) Molecular biology of chronic 
rejection and predictive value of biop- 
sies. In: Solez K, Racusen LC, Billing- 
ham ME (eds) Solid organ transplant 
rejection. Marcel Dekker, New York, 
83. Heemann UW, Azuma H, Tullius SG, 
Mackenzie H, Brenner BM, Tilney NL 
(1994) The contribution of reduced 
functioning mass to chronic kidney al- 
lograft dysfunction in rats. Transplan- 
tation 58: 1317-1322 
84. Heemann UW, Tullius SG, Azuma H, 
Tihey NL (1996) Early patterns of 
cellular infiltration and cytokine and 
extracellular matrix protein expres- 
sion reflect reperfusion injury after 
cardiac transplantation in rats. In: 
Faist E (ed) The immune consequenc- 
es of trauma, shock and sepsis. Pabst 




85. Heer de E, Davidoff A, van der Wal A, 
van Geest M, Paul LC (1994) Chronic 
renal allograft rejection in the rat. 
Transplantation-induced antibodies 
against basement membrane antigens. 
Lab Invest 70: 494-502 
86. Hirt SW, You XM, Moller F, Boeke K, 
Ernst M, Starke M, Spranger U, Wott- 
ge HU (1999) Early treatment of acute 
rejection prevents chronic rejection in 
a rat model of allogenic left lung 
transplantation. Transpl Proc 31: 
87. Van der Hoeven JAB, Ploeg RJ, Pos- 
tema F, Molema G, de Vos P, Girbes 
ARJ, Van Suylichem PTR, ter Horst 
GJ (1999) Induction of organ dysfunc- 
tion and activation of inflammatory 
markers in donor liver and kidney 
during hypotensive brain death. 
Transplant Proc 31: 1006-1007 
88. Hornick P, Smith J, Pomerance A, 
Mitchell A, Banner N, Rose M, Ya- 
coub M (1997) Influence of acute re- 
jection episodes, HLA matching, and 
donorlrecipient phenotype on the de- 
velopment of 'early' transplant-associ- 
ated coronary artery disease.Circula- 
tion 96: 148-153 
89. Hosenpud JD, Edwards EB, Lin HM, 
Daily OP (1996) Influence of HLA 
matching on thoracic transplant out- 
comes. An analysis from the UNOS/ 
ISHLT Thoracic Registry. Circulation 
94: 170-174 
90. Hosenpud JD, Mauck KA, Hogan KB 
(1997) Cardiac allograft vasculopathy: 
IgM antibody responses to donor-spe- 
cific vascular endothelium. Transplan- 
tation 63: 1602-1606 
91. Hruban RH, Beschorner WE, Baum- 
gartner WA,Augustine SM, Ren H, 
Reitz BA, Hutchins GM (1990) Ac- 
celerated arteriosclerosis in hear 
transplant recipients is associated with 
a T-lymphocyte-mediated endothelia- 
litis. Am J Patholl37: 871-882 
92. Humar A, Kerr S, Hassoun A, Gran- 
ger D, Suhr B, Matas A (1993) The as- 
sociation between acute rejection and 
chronic rejection in kidney transplan- 
tation. Transpl Proc 31: 1302-1303 
93. Ibrahim S, Jacobs F, Zukin Y, Enri- 
quez D, Holt D, Baldwin W 31d, Sanfi- 
lippo F, Ratner LE (1996) Immuno- 
histochemical manifestations of uni- 
lateral kidney ischemia. Clin Trans- 
plant 10: 646-652 
Granger DN (1990) Hypoxia/reoxy- 
genation increases the permeability of 
endothelial cell monolayers: role of 
oxygen radicals. Free Radic Biol Med 
1005-1006 
94. Inauen W, Payne DK, Kvietys PR, 
9: 219-223 
~~ 
95. Isaka Y, Fujuwara Y, Ueda N, Kaneda 
Y, Kamada T, Imai E (1993) Glomer- 
ulosclerosis induced by in vivo trans- 
fection of transforming growth factor 
/3 or platelet derived growth factor 
gene into the rat kidney. J Clin Invest 
96. Isoniemi HM, Krogerus L, Von Wille- 
brand E, Taskinen E, Ahonen J, Hayry 
P (1992) Histopathological findings in 
well-functioning, long-term renal allo- 
grafts. Kidney Int 41: 155-160 
Matsumiya G, Nakata S, Shimazaki Y, 
Matsuda H (1995) Evidence that graft 
coronary arteriosclerosis begins in the 
early phase after transplantation and 
progresses without chronic immunore- 
action. Histopathological analysis us- 
ing a retransplantation model. Trans- 
plantation 6 0  1073-1079 
98. Jain A, Fung JJ, Reyes J, Kashyap R, 
Rohal S ,  Rakela J, Starzl TE (1998) 
Primary liver transplantation in in- 
fants, children, adults, and se- 
niors:1000 consecutive patients from 
single centre with 5 to 8 years actual 
follow-up. Abstract book, XVII World 
Congress Transplantation Society, 
Montreal 
99. Jeannet M, Pinn VW, Flax MH, Rus- 
sell PS (1970) Humoral antibodies in 
renal allotransplantation in man. 
N Engl J Med 282: 111-117 
100. Katznelson S, Gjertson DW, Cecka JM 
(1995) The effect of race and ethnicity 
on kidney allograft outcome. In: Tera- 
saki PI (ed) Clinical Transplant 1995. 
UCLA Tissue Typing Laboratory, Los 
Angeles, CA, pp 379-394 
101. Knight RJ, Dikman S, Liu H, Marti- 
nelli GP (1997) Cold ischemic injury 
accelerates the progression to chronic 
rejection in a rat cardiac allograft. 
Transplantation 64: 1102-1107 
102. Koglin J, Glysing-Jensen T, Raisanen- 
Sokolowski A, Russell ME (1998) Im- 
mune sources of transforming growth 
factor-beta1 reduce transplant arterio- 
sclerosis: insight derived from a 
knockout mouse model. Circ Res 83: 
92: 2597-2601 
97. Izutani H, Miyagawa S, Shirakura R, 
652-660 
103. Koskinen P, Lemstrom K, Hayry P 
(1995) How cyclosporine modifies his- 
tological and molecular events in the 
vascular wall during chronic rejection 
of rat cardiac allografts. Am J Path 
104. Kouwenhoven EA, de Bruin RWF, 
Heemann UW, Marquet RL, IJzer- 
mans JNM (1999) Late graft dysfunc- 
tion after prolonged cold ischemia of 
the donor kidney. Inhibition by cy- 
closporine. Transplantation 68: 
10041010 
146: 972-978 
105. Kroshus TJ, Kshettry VR, Savik K, 
John R, Hertz MI, Bolman RM 3Td 
(1997) Risk factors for the develop- 
ment of bronchiolitis obliterans syn- 
drome after lung transplantation. 
J Thorac Cardiovasc Surg 114: 195-202 
106. Kusaka M, Ziai F, Hancock WH, Til- 
ney NL, Mackenzie HS (1999) Sys- 
temic hypertension accelerates chron- 
ic rejection of renal allografts in the 
rat. Transplant Proc 31: 869 
107. Land W, Schneeberger H, Schleibner 
S ,  Illner WD, Abendroth D, Rutili G, 
Arfors KE, Messmer K (1994) The 
beneficial effect of human recombi- 
nant superoxide dismutase on acute 
and chronic rejection events in recipi- 
ents of cadaveric renal transplants. 
Transplantation 57: 211-217 
108. Lautenschlager I, Hockerstedt K, Ja- 
lanko H, Loginov R, Salmela K, 
Taskinen E, Ahonen J (1997) Persis- 
tent cytomegalovirus in liver allografts 
with chronic rejection. Hepatology 25: 
190-194 
109. Lautenschlager I, Soots A, Krogerus 
L, Kauppinen H, Saarinen 0, Brug- 
geman C, Ahonen J (1997) Effect of 
cytomegalovirus on an experimental 
model of chronic renal allograft rejec- 
tion under triple-drug treatment in the 
rat. Transplantation 64: 391-398 
110. Lemstrom K, Bruning J, Bruggeman 
C, Lautenschlager I, Hayry P (1993) 
Cytomegalovirus infection enhances 
smooth muscle cell proliferation and 
intimal thickening of rat aortic allo- 
grafts. J Clin Invest 92: 549-558 
Daemen M, Bruggeman C, Hayry P 
(1995) Cytomegalovirus antigen ex- 
pression, endothelial cell proliferation, 
and intimal thickening in rat cardiac 
allografts after cytomegalovirus infec- 
tion. Circulation 92: 2594-2604 
112. Ley K, Tedder TF (1995) Leucocyte 
interactions with vascular endotheli- 
um-New insights into selectin-mediat- 
ed attachment and rolling. J Immunol 
111. Lemstrom K, Koskinen P, Krogerus L, 
155: 525-528 
113. Libby F', Salamon RN, Payne DD, 
Schoen FJ, Pober JS (1989) Functions 
of vascular wall cells related to devel- 
opment of transplantation-associated 
coronary arteriosclerosis. Transpl Proc 
21: 3677-3684 
114. Libby P, Takana H (1994) The patho- 
genesis of coronary arteriosclerosis 
(chronic rejection) in transplanted 
hearts. Clin Transplantation 8: 
3 13-31 8 
398 
115. Lindholm A, Ohlman S, Albrechtsen 
D, Tufveson G, Persson H, Persson 
NH (1993) The impact of acute rejec- 
tion episodes on long-term graft func- 
tion and outcome in 1347 primary ca- 
daveric renal transplants treated by 3 
cyclosporine regimens. Transplanta- 
tion 7: 343-352 
116. Lou H,  Kodama T, Zhao J, Maurice P, 
Wang YN, Katz N, Foegh ML (1996) 
Inhibition of transplant coronary arte- 
riosclerosis in rabbits by chronic oest- 
radio1 treatment is associated with ab- 
olition of MHC class I1 antigen ex- 
pression. Circulation 94: 3355-3361 
117. Mackenzie HS, Azuma H, Rennke 
HG, Tilney NL, Brenner BM (1995) 
Renal mass as a determinant of late 
allograft outcome: insights from ex- 
perimental studies in rats. Kidney Int 
52: 3 8 4 2  
118. Marlin SD, Springer TA (1987) Puri- 
fied intercellular adhesion moleclule-1 
(ICAM-1) is a ligand for lymphocyte 
function-associated antigen-1 (LFA- 
1). Cell 51: 813-819 
Moore SA, Wewers MD (1995) 
Monocyte Fc gamma receptor cross- 
linking induces IL-8 production. J Im- 
munoll55: 3161-3167 
120. Marsh CB, Wewers MD, Tan LC, Ro- 
vin BH (1997) Fc gamma receptor 
crosslinking induces peripheral blood 
mononuclear cell MCP-1 expression. 
J Immunoll58: 1078-1084 
121. Martin S, Dyer PA, Mallick NP, Gokal 
R, Harris R, Johnson RWG (1987) 
Post-transplant antidonor lympho- 
cytotoxic antibody production in rela- 
tion to graft outcome. Transplantation 
44: 50-53 
122. Massy ZA, Guijarro C, Wiederkehr 
MR, Ma JZ, Kasiske BL (1996) 
Chronic renal allograft rejection: im- 
munologic and non-immunologic risk 
factors. Kidney Int 49: 518-524 
123. Matas A, Gillingham K, Sutherland 
D E  (1993) Half-life and risk factors for 
kidney transplant outcome- impor- 
tance of death with function. Trans- 
plantation 55: 757-761 
124. Matas A (1994) Chronic rejection in 
renal transplants - Risk factors and 
correlates. Clin Transplantation 8: 
125. Matas AJ, Gillingham KJ, Payne WD, 
119. Marsh CB, Gadek JE, Kindt GC, 
332-335 
Najarian JS (1994) The impact of an 
acute rejection epsiode on long-term 
renal allograft survival (t1/2). Trans- 
plantation 57: 857-859 
126. Matsuyama T, Yamada A, Kay J, Ya- 
mada KM, Akiyama SK, Schlossman 
SF, Morimoto C (1989) Activation of 
CD4 cells by fibronectin and anti-CD3 
antibody. A synergistic effect mediat- 
ed by VLA-5 fibronectin receptor 
complex. J Exp Med 170: 1133-38 
127. Mayadas TN, Johnson RC, Rayburn 
H, Hynes RO, Wagner D D  (1993) 
Leucocyte rolling and extravasation 
are severely compromised in P-selec- 
tin-deficient mice. Cell 74: 541-554 
128. McDonald K, Rector TS, Braunlin 
EA, Kubo SH, Olivari MT (1989) As- 
sociation of coronary artery disease in 
cardiac transplant recipients with cy- 
tomegalovirus infection. Am J Pathol 
129. McGiffin DC, Savunen T, Kirklin JK, 
Naftel DC, Bourge RC, Paine TD, 
White-Williams C, Sisto T, Early L 
(1995) Cardiac transplant coronary ar- 
tery disease. A multivariable analysis 
of pretransplantation risk factors for 
disease development and morbid 
events. J Thorac Cardiovasc Surg 109: 
64: 359-362 
1081-1088 
130. Meiser BM, Wolf S, Devens CH, 
Wenke K, Thiery J, Kreuzer E, Ham- 
mer C, Billingham ME, Reichart B 
(1992) Continuous infusion of angio- 
peptin significantly reduces accelerat- 
ed graft vessel disease induced by 
FK506 in a rat heart allograft model. 
Transpl Proc 24: 1671-1672 
131. Mennander A, Raisanen A, Paavonen 
T, Hayry P (1993) Chronic rejection in 
the rat aortic al1ograft.V. Mechanism 
of the angiopeptin (BIM 23014C) ef- 
fect on the generation of allograft ar- 
teriosclerosis. Transplantation 55: 
124-28 
versibility of allograft arteriosclerosis 
after retransplantation to donor strain. 
Transplantation 62: 526-529 
133. Mennander AA, Tikkanen MJ, Raisa- 
nen-Sokolowski AK, Ustinov J, Hayry 
P (1993) Chronic rejection in rat allo- 
grafts. IV. Effect of hypercholester- 
olemia in allograft arteriosclerosis. 
J Heart Lung Transplant 12 :123-132 
134. Michel J-B, Plissonier D,  Bruneval P 
(1992) Effect of perindopril on the im- 
mune arterial wall remodeling in the 
rat model of arterial graft rejection. 
Am J Med 92:S39-46 
135. Miles AM, Sumrani N, John S, Mar- 
kell MS, Distant DA, Maursky V, 
Hong JH, Friedman EA, Sommer B 
(1996) The effect of kidney size on ca- 
daveric renal allograft outcome. 
Transplantation 61: 894-897 
132. Mennander A, Hayry P (1996) Re- 
136. Monga G, Mazzucco G, Novara R, 
Reale L (1990) Intertubular capillary 
changes in kidney allografts: an ultra- 
structural study in patients with trans- 
plant glomerulopathy. Ultrastruct Pa- 
tho1 14: 201-209 
137. Nadeau KC, Azuma H, Tihey NL 
(1995) Sequential cytokine dynamics 
in chronic rejection of rat renal allo- 
grafts: roles for cytokines RANTES 
and MCP-1. Proc Natl Acad Sci USA 
92: 8729-33 
138. Nagano H,  Libby P, Taylor MK, Ha- 
segawa s, Stim JL, Becker G, Tilney 
NL (1998) Coronary arteriosclerosis 
after T-cell mediated injury in trans- 
planted mouse hearts: role of interfer- 
on-y. Am J Patholl52: 1187-1197 
139. Nagano H,  Mitchell RN, Taylor MK, 
Hasegawa S, Tilney NL, Libby P 
(1997) Interferon-y deficiency pre- 
vents coronary arteriosclerosis but not 
myocardial rejection in transplanted 
mouse hearts. J Clin Invest 100: 
550-557 
140. Nagano H,  Tilney NL, Stinn JL, Beck- 
er G, Hasegawa s, Libby P, Mitchell 
RN (1999) Deficiencies of IL-4 or 
TNF-a R1 do not diminish graft arte- 
riosclerosis in cardiac allografts. 
Transplant Proc 31: 152 
141. Nakagawa T, Sukhova GK, Rabkin E, 
Winters GL, Schoen FJ, Libby P 
(1995) Acute rejection accelerates 
graft coronary disease in transplanted 
rabbit hearts. Circulation 92: 987-993 
142. Novick AC, Gephardt G, Guz B, 
Steinmuller D,  Tubbs RR (1991) 
Long-term follow-up after partial re- 
moval of a solitary kidney. N Engl J 
Med 325: 1058-1062 
erland S, Donaldson PT, Harvey F, 
Portmann B, Calne RY, Williams R 
(1988) Cytomegalovirus infection and 
donor/recipient HLA antigens: Inter- 
dependent co-factors in pathogenesis 
of vanishing bile duct syndrome after 
liver transplantation. Lancet 2: 
143. O’Grady JG, Alexander GJM, Suth- 
302-305 
144. O’Malley KS, Cook DJ, Flechner SM, 
McCarthy JF, Klingman LL, Modlin 
CS, Goldfarb DA, Dennis VW, Novick 
AC (1998) HLA-antibody production 
correlates strongly with chronic renal 
allograft rejection. Abstract XVII 
World Congress Transplantation Soci- 
ety, Montreal 
145. Ojo AO, Wolfe RA, Held PJ, Port FK, 
Schmouder RL (1997) Delayed graft 
function: risk factors and implications 
for renal allograft survival. Transplan- 
tation 63: 968-974 
399 
146. Opelz G for the Collaborative Trans- 
plant Study (1997) Chronic graft loss 
in kidney and heart transplant recipi- 
ents. In: Touraine JL, Traeger J, BC- 
tuel H, Dubernaed JM, Revillard JP, 
Dupuy C (eds) Late graft loss, Kluwer 
Academic, London, pp 3-12 
147. Opelz G, for the Collaborative trans- 
plant study (1997) Critical evaluation 
of the association between acute and 
chronic graft rejection in kidney and 
heart transplant recipients. Transplant 
proc 29: 73-76 
148. Opelz G, Wujciak T, Ritz E (1998) 
Association of chronic kidney graft 
failure with recipient blood pressure. 
Collaborative Transplant Study. Kid- 
ney Int 53: 217-222 
149. Paul LC, Baldwin WM, Van Es LA 
(1985) Vascular endothelial alloanti- 
gens in renal transplantaton. Trans- 
plantation 40  117-123 
150. Paul LC. Havrv P. Foeeh M. Dennis 
151 
u ,  
MJ, Mihatsck M, Larsson E, Fellstrom 
B (1993) Diagnostic criteria for chron- 
ic rejection/accelerated graft athero- 
sclerosis in heart and kidney trans- 
plants: Proposal from the Fourth Al- 
exis Carrel Conference on Chronic re- 
jection and accelerated arteriosclero- 
sis in transplanted organs. Transplant 
Proc 25: 2020-2021 
Paul LC, Muralidharan J, Muzaffar 
SA, Manting EH, Valentin JF, de Heer 
E, Kashgarian M (1998) Antibodies 
against mesangial cells and their 
secretory products in chronic renal al- 
lograft rejection in the rat. Am J Pa- 
tho1 152: 1209-1223 
152. Paul LC, Saito K, Davidoff A, Bene- 
diktsson H (1996) Growth factor tran- 
scripts in rat renal transplants. Am J 
Kidney Dis 2 8  441450 
153. Peters TG, Shaver TRS, Ames J E  4th, 
Santiago-Delphin EA, Jones KW, 
Blanton JW (1995) Cold ischemia and 
outcome in 17 937 cadaveric kidney 
transplants. Transplantation 59: 
154. Petrossian GA, Nichols AB, Marboe 
CC, Sciacca R, Rose EA, Smith CR, 
Cannon PJ, Reemtsma K, Powers E R  
(1989) Relation between survival and 
development of coronary disease and 
anti-HLA antibodies after cardiac 
transplantation. Circulation 8 0  
191-196 
122-1 25 
155. Pirsch JD, Ploeg RJ, Gange S, 
D’Alessandro AM, Knechtle SJ, Sol- 
linger HW, Kalayoglu M, Belzer FO 
(1996) Determinants of graft survival 
after renal transplantation. Transplan- 
tation 61: 1581-1586 
156. Pober JS, Gimbrone MA, Lapierre 
LA, Mendrick DL, Fiers W, Rothlein 
R, Springer TA (1986) Overlapping 
patterns of activation of human endo- 
thelial cells by interleukin-1, tumor 
necrosis factor, and immune interfer- 
on. J Immunoll37: 1893-1896 
157. Ponticelli C, Mantaginino G, Aroldi 
A, Angelini C, Braga M, Tarantino A 
(1993) Hypertension after renal trans- 
plantation. Am J Kidney Dis 
21:S73-78 
158. Porter KA, Owen K, Mowbray JF, 
Thomson WB, Kenyon JR, Peart WS 
(1963) Obliterative vascular changes 
in four human kidney homotrans- 
plants. Br Med J 14: 639-651 
159. Poston RS Jr, Billingham ME, Pollard 
J, Hoyt EG, Robbins R C  (1997) Ef- 
fects of increased ICAM-1 on reperfu- 
sion injury and chronic graft vascular 
disease. Ann Thorac Surg 64: 1004-12 
160. Pratschke J, Kusaka M, Wilhelm MJ, 
Hancock WW, Tilney NL (1999) 
Acute rejection of rat renal allografts 
is accelerated by donor brain death. 
Transplant Proc 31: 874-875 
Hancock WW, Tilney NL (1999) Acti- 
vation of proinflammatory genes in 
somatic organs as a consequence of 
brain death. Transplant Proc 31: 
1003-1005 
162. Radovancevic B, Poindexter S, Bir- 
ovljev S, Velebit V, McAllister HA, 
Duncan JM, Vega D, Lonquist J, Bur- 
nett CM, Frazier OH (1990) Risk fac- 
tors for the development of accelerat- 
ed coronary artery disease in cardiac 
transplant recipients. Eur J Cardio- 
thorac Surg 4: 309-312 
hypertenisve therapy modify chronic 
allograft failure? Kidney Int 
161. Pratschke J, Wilhelm MJ, Kusaka M, 
163. Raine AEG (1995) Does anti- 
48:S107-111 
164. Ratner LE, Cigarroa FG, Bender JS, 
Magnuson T, Kraus ES (1997) Trans- 
plantation of single and paired pediat- 
ric kidneys into adult recipients. J Am 
Coll Surg 185: 437445 
165. Reed EF, Hong B, Ho E, Harris PE, 
Weinberger J, Suciu-Foca N (1996) 
Monitoring of soluble HLA alloanti- 
gens and anti-HLA antibodies identi- 
fies heart allograft recipients at risk of 
transplant-associated coronary dis- 
ease. Transplantation 61: 566-572 
bins RC, Yun KL, Nitschke M, Berry 
GJ, Morris RE, Theodore J, Reitz BA 
(1996) Stanford experience with oblit- 
erative bronchiolitis after lung and 
heart-lung transplantation. Ann Tho- 
rac Surg 62: 1467-1472 
166. Reichenspurner H, Girgis RE, Rob- 
167. Rice GE, Bevilacqua MP (1989) An 
inducible endothelial cell surface gly- 
coprotein mediates melanoma adhe- 
sion. Science 246: 1303-1306 
168. Rose EA, Pepino P, Barr ML, Smith 
CR, Ratner AJ, Ho E, Berger C (1992) 
Relation of HLA antibodies and graft 
atherosclerosis in human cardiac 
transplant recipients. J Heart Lung 
Transplant 11:S120-23 
169. Ross R (1993) The pathogenesis of 
atherosclerosis: a perspective for 
1990 s. Nature 362: 801-809 
170. Rossen RD, Butler WT, Reisberg MA, 
Brooks DK, Leachman RD, Milam 
JD, Mittal KK, Montgomery JR, Nova 
JJ, Rochelle DG (1971) Immunofluo- 
rescent localization of human immu- 
noglobulin in tissues from cardiac al- 
lograft recipients. J Imrnunol 106: 
171. Russell ME, Hancock WW, Akalin E, 
Wallace AF, Glysing-Jensen T, Willett 
TA, Sayegh MH (1996) Chronic cardi- 
ac rejection in the Lew to F344 rat 
model. Blockade of CD28-B7 costim- 
ulation by CTLA4Ig modulates T cell 
and macrophage activation and atten- 
uates arteriosclerosis. J Clin Invest 97: 
171-180 
833-838 
172. Russell ME, Wallace AF, Hancock 
WW, Sayegh MH, Adams DH, Sibinga 
NE, Wyner LR, Karnovsky MJ (1995) 
Upregulation of cytokines associated 
with macrophage activation in the Le- 
wis-to-F344 rat transplantation model 
of chronic cardiac rejection. Trans- 
plantation 59: 572-578 
173. Russell PS, Chase CM, Colvin RB 
(1997) Alloantibody- and T cell-medi- 
ated immunity in the pathogenesis of 
transplant arteriosclerosis: lack of pro- 
gression to sclerotic lesions in B cell- 
deficient mice. Transplantation 64: 
1531-1536 
174. Russell PS, Chase CM, Winn HJ, Col- 
vin RB (1994) Coronary atherosclero- 
sis in transplanted mouse hearts. 
11. Importance of humoral immunity. 
J Immunoll52: 5135-5141 
175. Saito S, Motomura N, Lou H, Ram- 
well PW, Foegh ML (1997) Specific 
effects of oestrogen on growth factors 
and MHC class I1 expression in rat 
aorta allograft. J Thorac Cardiovasc 
Surg 114: 803-10 
176. Salamon RN, Hughes CCW, Schoen 
FJ, Payne DD, Pober JS, Libby P 
(1991) Human coronary transplanta- 
tion-associated arteriosclerosis: evi- 
dence for a chronic immune reaction 
to activated graft endothelial cells. Am 
J Patholl38: 791-798 
400 
177. Salomon D R  (1991) An alternative 
view minimizing the significance of 
cyclosporine nephrotoxicity and in fa- 
vor of enhanced immunosuppression 
for long-term kidey transplant recipi- 
ents. Transplant Proc 23: 2115 
178. Schmid C, Heemann U, Tilney NL 
(1997) Factors contributing to the de- 
velopement of chronic rejection in 
heterotopic rat heart transplantation. 
Transplantation 64: 222-228 
179. Schweitzer EJ, Matas AJ, Gillingham 
K, Payne WD, Gores PF, Dunn DL, 
Sutherland DER, Najarian JS (1991) 
Causes of renal allograft loss: progress 
in the 80 s, challenges for the 90 s. Ann 
Surg 214: 679-688 
180. Scott C, Colquhoun I, Gould K, Au J, 
Dark J (1992) Determinants of graft 
arteriosclerosis after heart transplan- 
tation. Transplant Int 5:S238-241 
181. Serrick C, La Franchesca S, Giaid A, 
Shennib H (1995) Cytokine IL-2, 
TNFa and IFNy release after ischemia 
reperfusion injury in a novel lung au- 
tograft animal model. Am J Respir 
Crit Care Med 152: 277-282 
182. Sharrock CEM, Man S, Wanachi- 
wanawin W, Batchelor JR (1987) 
Analysis of the T cell repertoire in 
man. Transplantation 43: 699-703 
183. Shi C, Feinberg MW, Zhang D, Pate1 
A, Sim CU, Dong ZM, Chapman SM, 
Gutierrez-Ramos JC, Wagner DD, Si- 
binga NE, Haber E (1999) Donor 
MHC and adhesion molecules in 
transplant arteriosclerosis. J Clin In- 
vest 103: 469-474 
Fletcher DL Jr, Newell JB, Haber E 
(1996) Immunologic basis of trans- 
plant-associated arteriosclerosis. Proc 
Natl Acad Sci USA 93: 4051-4056 
185. Shihab FS, Yamamoto T, Nast CC, 
Cohen AH, Noble NA, Gold LI, Bor- 
der WA (1995) Transforming growth 
factor$ and matrix protein expression 
in acute and chronic rejection of hu- 
man renal allografts. J Am SOC Ne- 
phrol6: 286294 
186. Shimura T, Morrison AB (1975) A 
progressive glomerulosclerosis occur- 
ring in partial five-sixth nephrectom- 
ized rats. Am J Pathol79: 95-106 
187. Shin YT, Adams DH, Wyner LR, 
Akalin E, Sayegh MH, Karnovsky MJ 
(1995) Intrathymic injection of donor 
splenocytes plus systemic antilympho- 
cyte serum or antilymphocyte serum 
alone prolongs cardiac allograft sur- 
vival and inhibits graft arteriosclerosis 
in the Lewis-to-F344 chronic rejection 
model. Transplant Proc 27: 2112-2114 
184. Shi C, Lee WS, He Q, Zhang D, 
188. Shoskes DA, Cecka JM (1998) Dele- 
terious effects of delayed graft func- 
tion in cadaveric renal transplant re- 
cipients independent of acute rejec- 
tion. Transplantation 66: 1697-1701 
189. Shoskes DA, Parfrey NA, Halloran PF 
(1990) Increased major histocompati- 
bility complex antigen expression in 
unilateral ischemic acute tubular ne- 
crosis in the mouse. Transplantation 
49: 201-207 
190. Shoskes DA, Wood KJ (1994) Indirect 
presentation of MHC antigens in 
transplantation. Immunol Today 15: 
191. Sibley RK (1997) Histopathology of 
32-38 
chronic rejection. In: Touraine JL (ed) 
Late graft loss, Kluwer Academic, 
London, pp 13-23 
192. Smith JD, Danskine AJ, Rose ML, 
Yacoub MH (1992) Specificity of lym- 
phocytotoxic antibodies formed after 
cardiac transplantation and correla- 
tion with rejection episodes. Trans- 
plantation 53: 1358-1362 
193, Smith JD, Rose ML, Pomerance A, 
Burke M, Yacoub MH (1995) Reduc- 
tion of cellular rejection and increase 
in longer-term survival after heart 
transplantation after HLA-DR 
matching. Lancet 346: 1318-1322 
194. Soin AS, Rasmussen A, Jamieson NV, 
Watson CJ, Friend PJ, Wight DG, 
Calne RY (1995) CsA levels in the 
early posttransplant period-predictive 
of chronic rejection in liver transplan- 
tation? Transplantation 59: 1119-1123 
H,Burdick JF, Cohen AH, Colvin RB, 
Croker BP, Droz D, Dunnill MS, Hal- 
loran PF, et a1 (1993) International 
standardization of nomenclature and 
criteria for the histologic diagnosis of 
renal allograft rejection: the BANFF 
working classification of kidney trans- 
plant patology. Kidney Int 44: 411422 
dardization of criteria for histologic 
diagnosis of chronic rejection in renal 
allografts. Clin Transplantation 8: 
197. Springer TA (1995) Traffic signals on 
endothelium for lymphocyte recircu- 
lation and leucocyte emigration. Annu 
Rev Physiol57: 827-872 
198. Stein-Oakley A, Jablonski P, Tzanidis 
A, Baxter K, Howden BO, Marshall 
VC, Thomson NM (1993) Develop- 
ment of chronic injury and nature of 
interstial infiltrate in a model of 
chronic renal allograft rejection. 
Transplantation 56: 1299-1305 
195. Solez K, Axelsen RA, Benediktsson 
196. Solez K (1994) International stan- 
345-350 
199. Stoltenberg RL, Geraghty J, Steele 
DM, Kennedy E, Hullett DA, Sollin- 
ger HW (1995) Inhibition of intimal 
hyperplasia in rat aortic allografts with 
cyclosporin. Transplantation 60: 
200. Strom TB, Roy-Chaudhury P, Manfro 
R, Zheng XX, Nickerson PW, Wood 
K, Bushel1 A (1996) The ThUTh2 par- 
adigm and the allograft response. Curr 
Opin Immunol8: 688-693 
201. Suciu-Foca N, Reed E, D’Agati VD, 
Ho E, Cohen DJ, Benvenistry AI, 
McCabe R, Brensilver JM, King DW, 
Hardy MA (1991) Soluble HLA anti- 
gens, anti-HLA antibodies, and anti- 
idiotypic antibodies in the circulation 
of renal transplant recipients. Trans- 
plantation 51: 593-601 
C,Harris P, Yu XP, Sun YK, H o  E, 
Rose E, Reemstma K, King DW 
(1991) The role of anti-HLA antibod- 
ies in heart transplantation. Trans- 
plantation 51: 716-724 
203. Sumrani N, Delaney V, Ding ZK, Butt 
K, Hong J (1990) HLA-identical renal 
transplants: impact of cyclosporine on 
intermediate-term survival survival 
and renal function. Am J Kidney Dis 
16: 417422 
(1996) Posttransplant serum creati- 
nine under the curve predicts renal al- 
lograft outcome. Transplant Proc 28: 
993-998 
202. Suciu-Foca N, Reed E, Marboe 
204. Sumrani N, Hong J, Miles A, et a1 
356-357 
205. Sun H,  Subbotin V, Chen C, Aitouche 
A, Valdivia LA, Sayegh MH, Linsley 
PS, Fung JJ, Starzl TE, Rao AS (1997) 
Prevention of chronic rejection in 
mouse aortic allografts by combined 
treatment with CTLA4-Ig and anti- 
CD40 ligand monoclonal antibody. 
Transplantation 64: 1838-1843 
206. Suthanthiran M (1997) Molecular 
analyses of human renal allografts: 
Differential intragraft gene expres- 
sion during rejection. Kidney Int 58: 
15-21 
207. Takada M, Chandraker A, Nadeau 
KC, Sayegh MH, Tilney NL (1997) 
The role of the B7 costimulatory path- 
way in experimental ischemia/reperfu- 
sion injury. J Clin Invest 100: 
1199-1203 
208. Takada M, Nadeau KC, Hancock WW, 
Mackenzie HS, Shaw GD, Waaga AM, 
Chandraker A, Sayegh MH, Tihey NL 
(1998) Effects of explosive brain death 
on cytokine activation of peripheral 
organs in the rat. Transplantation 65: 
1533-1542 
401 
209. Takada M, Nadeau KC, Shaw GD, 
Marquette KA, Tilney NL (1997) The 
cytokine-adhesion molecule cascade 
in ischemiaheperfusion injury of the 
rat kidney. Inhibition by a soluble 
P-selectin ligand. J Clin Invest 99: 
2682-2690 
210. Takada M, Nadeau KC, Shaw GD, 
Tilney NL (1997) Prevention of late 
renal changes after initial ischemiahe- 
perfusion injury by blocking early se- 
lectin binding. Transplantation 64: 
1520-1525 
211. Tanaka H, Sukhova GK, Libby P 
(1994) Interaction of the allogeneic 
state and hypercholesterolemia in ar- 
terial lesion formation in experimental 
cardiac allografts. Arterioscler 
Thromb 14 734-445 
212. Terasaki PI, Cecka JM, Gjertson DW, 
Takemoto S (1995) High survival rates 
of kidney transplants from spousal and 
living unrelated donors. N Engl J Med 
213. Terasaki PI, Yuge J, Cecka JM, Gjert- 
333: 333-336 
son DW, Takemoto S, Cho Y (1993) 
Thirty-year trends in clinical kidney 
transplantation. In: Terasaki PI, Cecka 
JM (eds) Clinical Transplant 1993. 
UCLA Tissue Typing Laboratory, Los 
Angeles, CA, pp 553-562 
214. Thorogood J, Van Houwelingen HC, 
Van Roodt JJ, Zantvoort FA, Schreu- 
der GMT, Persijn G G  (1992) Long- 
term results of kidney transplantation 
in Eurotransplant. In: Paul LC, Solez 
K (eds) Organ Transplantation: Long 
term Results. Marcel Dekker, New 
York, pp 33-56 
Ksiazek T, Sjoliind M (1983) Pheno- 
type modulation in primary cultures of 
arterial smooth muscle cells. Differen- 
tiation 25: 156-167 
Strom TB, Graves MJ, Carpenter CB 
(1979) Rejected human renal allo- 
grafts: recovery and characteristics of 
infiltrating cells and antibody. Trans- 
plantation 28: 421426 
217. Troppmann C, Benedetti E, GruessneI 
RWG, Payne WD, Sutherland DE, 
Najarian JS, Matas AJ (1995) Re- 
transplantation after renal allograft 
loss due to noncompliance. Transplan- 
tation 59: 467471 
215. Thyberg J, Palmberg L, Nilsson J, 
216. Tilney NL, Gavaroy MR, Busch GJ, 
218. Troppmann C, Gillingham KJ, Bene- 
detti E, Almond PS, Gruessner RWG, 
Najarian JS, Matas AJ (1995) Delayed 
graft function, acute rejection, and 
outcome after cadaver renal trans- 
plantation. Transplantation 58: 
219. Tullius SG, Hancock WW, Heemann 
962-968 
UW, Azuma H, Tilney NL (1994) Re- 
versibility of chronic renal allograft 
rejection. Critical effect of time after 
transplantation suggests both host im- 
mune dependent and independent 
phases of progressive injury. Trans- 
plantation 58: 93-99 
220. Tullius SG, Heemann U, Hancock 
WW, Azuma H,  Tilney NL (1994) 
Long-term kidney isografts develop 
functional and morphologic changes 
that mimic those of chronic allograft 
rejection. Ann Surg 220: 425-435 
221. Tullius SG, Heemann UW, Azuma H 
(1994) Early ischemic injury leads to 
long-term functional and morphologic 
deterioration of naYve rat kidneys and 
may contribute to changes of chronic 
allograft rejection. Transplant Proc 26: 
2041 
222. Van Saase JLCM, Van der Woude FJ, 
Thorogood J, Hollander AA, van Es 
LA, Weening JJ, Bockel JM, Bruijn 
JA (1995) The relation between acute 
vascular and interstitial renal allograft 
rejection and subsequent chronic re- 
jection. Transplantation 59: 1280-1285 
223. Vanrentergem Y, Peeters J (1997) The 
impact of acute rejection on the long- 
term incidence after renal transplanta- 
tion. In: Touraine JL, et a1 (eds) Late 
graft loss. Kluwer Academic, London, 
pp 85-89 
224. Vereerstraeten P, Abramowicz D,  De 
Pauw L, Kinnaert P (1997) Absence of 
deleterious effect on long-term kidney 
graft survival of rejection episodes 
with complete functional recovery. 
Transplantation 63: 1739 
225. Wanders A, Akyiirek ML, Waltenber- 
ger J, Ren ZP, Stafberg C, Funa K, 
Larsson E, Fellstrom B (1995) Is- 
chemia-induced transplant arterioscle- 
rosis in the rat. Arterioscl Thromb 
Vasc Bioll5: 145-155 
226. Wasowska B, Wieder KJ, Hancock 
WW, Zheng XX, berse B, Binder J, 
Strom TB, Kupiec-Weglinski JW 
(1996) Cytokine and alloantibody net- 
works in long-term cardiac allografts 
in rat recipients treated with rapamy- 
cin. J Immunoll56: 395-404 
227. Weiser MR, Williams JP, Moore FD Jr, 
Kobzik L, Ma M, Hechtman HB, Car- 
roll MC (1996) Reperfusion injury of 
ischemic skeletal muscle is mediated 
by natural antibody and complement. 
J Exp Med 183: 2343-2348 
(1992) Cloning of the mouse endothe- 
lial selectins: expression of both E- and 
P-selectin is inducible by tumor necro- 
sis factor alpha. J Biol Chem 267: 
229. Wilhelm MJ, Pratschke J, Kusaka M, 
Hancock WW, Tihey NL (1999) Do- 
nor brain death affects tempo and in- 
tensity of acute rejection of rat cardiac 
allografts. Transplant Proc 31: 
1008-1 009 
230. Xiao F, Chong A, Shen, Yang J, Short 
J, Foster P, Sankary H, Jensik S, Mital 
D, McChesney L e t  a1 (1995) Pharma- 
cologically induced regression of 
chronic transplant rejection. Trans- 
plantation 60: 1065-1072 
Kobashigawa JA, Mier LW, Valentine 
HA, Ventura HO, Wiedermann J, Wi- 
lensky R (1995) Incidence and pro- 
gression of transplant coronary artery 
disease over 1 year: Results of a multi- 
center trial with use of intravascular 
ultrasound. J Heart Lung Transplant 
232. Yilmaz S, Hayry P (1993) The impact 
of acute episodes of rejection on the 
generation of chronic rejection in rat 
renal allografts. Transplantation 56: 
1153-1156 
(1995) Chronic renal allograft rejec- 
tion can be predicted by the surface 
area under the serum creatinine versus 
time curve. Transpl Proc 27: 927 
Bruggeman CA, Hayry PJ, Lemstrom 
KB (1996) Cytomegalovirus infection- 
enhanced chronic kidney allograft re- 
jection is linked with intercellular ad- 
hesion molecule-1 expression. Kidney 
Int 5 0  526-537 
Chronic rejection of rat renal allo- 
grafts I1 (1992) The impact of pro- 
longed ischemia time on transplant 
histology. Transplantation 53: 823-827 
236. Zwacka RM, Zhang Y, Halldorson J, 
Schlossberg H, Dudus L, Engelhardt 
JF (1997) CD4 + T-lymphocytes medi- 
ate ischemialreperfusion-induced in- 
flammatory responses in mouse liver. 
J Clin Invest 100: 279-289 
228. Weller A, Isenmann S, Vestweber 
15176-15183 
231. Yeung AC, Davis SF, Hauptman PJ, 
14: 215-220 
233. Yilmaz S, Kallio E, Yilmaz A, Hayry P 
234. Yilmaz S, Koskinen PK, Kallio E, 
235. Yilmaz S, Pavoonen T, Hayry P 
